Podcast appearances and mentions of bill newman

dreams catholic church indigenous peoples cornucopia bill newman

Play Episode Listen Later Oct 14, 2024 15:06

10/14/24: UMass Prof Amilcar Shabazz: Indigenous People's Day and the Catholic Church's position on reparations. Nate Clifford, co-owner, Cornucopia, & Jamie Morey: YES on ballot question 4. Megan Zinn with author Marisa Labozzetta: “Men Who Walk in Dreams.”

Vivienne Parry, Professor Bill Newman, Anita Hanson and Professor Matt Brown: Can genomic testing prevent adverse drug reactions?

The G Word

Play Episode Listen Later Aug 14, 2024 36:49

Pharmacogenomics plays a critical role in personalised medicine, as some adverse drug reactions are genetically determined. Adverse drugs reactions (ADRs) account for 6.5% of hospital admissions in the UK, and the application of pharmacogenomics to look at an individuals response to drugs can significantly enhance patient outcomes and safety. In this episode, our guests discuss how genomic testing can identify patients who will respond to medications and those who may have adverse reactions. We hear more about Genomics England's collaboration with the Medicines and Healthcare products Regulatory Agency in the Yellow Card Biobank and our guests discuss the challenges of implementing pharmacogenomics into the healthcare system. Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Anita Hanson, Research Matron and the Lead Research Nurse for clinical pharmacology at Liverpool University Hospitals NHS Foundation Trust, and Professor Bill Newman, Professor of translational genomic medicine at the Manchester Center for Genomic Medicine, and Professor Matt Brown, Chief Scientific Officer at Genomics England. "I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record." To learn more about Jane's lived experience with Stevens-Johnson syndrome, visit The Academy of Medical Sciences' (AMS) YouTube channel. The story, co-produced by Areeba Hanif from AMS, provides an in-depth look at Jane's journey. You can watch the video via this link: https://www.youtube.com/watch?v=v4KJtDZJyaA Want to learn more about personalised medicine? Listen to our Genomics 101 episode where Professor Matt Brown explains what it is in less than 5 minutes: https://www.genomicsengland.co.uk/podcasts/genomics-101-what-is-personalised-medicine You can read the transcript below or download it here: https://www.genomicsengland.co.uk/assets/documents/Podcast-transcripts/Can-genomic-testing-prevent-adverse-drug-reactions.docx Vivienne: Hello and welcome to Behind the Genes. Bill: What we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So, a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing. Vivienne: My name's Vivienne Parry and I'm head of public engagement at Genomics England, and today we'll be discussing the critical role of pharmacogenomics in personalised medicine, highlighting its impact on how well medicines work, their safety, and on patient care. I'm joined today by Professor Bill Newman, professor of translational genomic medicine at the Manchester Centre for Genomic Medicine, Anita Hanson, research matron, a fabulous title, and lead research nurse for clinical pharmacology at the Liverpool University Hospital's NHS Foundation Trust, and Professor Matt Brown, chief scientific officer for Genomics England. And just remember, if you enjoy today's episode, we'd love your support, so please like, share and rate us on wherever you listen to your podcasts. So, first question to you, Bill, what is pharmacogenomics? Bill: Thanks Viv. I think there are lots of different definitions, but how I think of pharmacogenetics is by using genetic information to inform how we prescribe drugs, so that they can be safer and more effective. And we're talking about genetic changes that are passed down through families, so these are changes that are found in lots of individuals. We all carry changes in our genes that are important in how we transform and metabolise medicines, and how our bodies respond to them. Vivienne: Now, you said pharmacogenetics. Is it one of those medicine things like tomato, tomato, or is there a real difference between pharmacogenetics and pharmacogenomics? Bill: So, people, as you can imagine, do get quite irate about this sort of thing, and there are lots of people that would contest that there is a really big important difference. I suppose that pharmacogenetics is more when you're looking at single changes in a relatively small number of genes, whereas pharmacogenomics is a broader definition, which can involve looking at the whole genome, lots of genes, and also whether those genes are switched on or switched off, so the expression levels of those genes as well would encompass pharmacogenomics. But ultimately it's using genetic information to make drug prescription safer and more effective. Vivienne: So, we're going to call it pharmacogenomics and we're talking about everything, that's it, we'll go for it. So Matt, just explain if you would the link between pharmacogenomics and personalised medicine. And I know that you've done a big Genomics 101 episode about personalised medicine, but just very briefly, what's the link between the two? Matt: So, personalised medicine's about using the right dose of the right drug for the right individual. And so pharmacogenomics helps you with not only ensuring that you give a medication which doesn't cause problems for the person who receives it, so an adverse drug reaction, but also that they're actually getting the right dose. Of course, people's ability to metabolise, activate and respond to drugs genetically is often genetically determined, and so sometimes you need to adjust the dose up or down according to a person's genetic background. Vivienne: Now, one of the things that we've become very aware of is adverse drug reactions, and I think they account for something like six and a half percent of all hospital admissions in the UK, so it's absolutely huge. Is that genetically determined adverse drug reactions? Matt: So, the answer to that is we believe so. There's quite a bit of data to show that you can reduce the risk of people needing a hospital admission by screening genetic markers, and a lot of the very severe reactions that lead to people being admitted to hospital are very strongly genetically determined. So for example, there are HLA types that affect the risk of adverse drug reactions to commonly used medications for gout, for epilepsy, some HIV medications and so on, where in many health services around the world, including in England, there are already tests available to help prevent those leading to severe reactions. It's likely though that actually the tests we have available only represent a small fraction of the total preventable adverse drug reactions were we to have a formal pre-emptive pharmacogenomics screening programme. Vivienne: Now, I should say that not all adverse drug reactions are genetic in origin. I mean, I remember a rather nasty incident on the night when I got my exam results for my finals, and I'd actually had a big bee sting and I'd been prescribed antihistamines, and I went out and I drank rather a lot to celebrate, and oh my goodness me, I was rather ill [laughter]. So, you know, not all adverse drug reactions are genetic in origin. There are other things that interact as well, just to make that clear to people. Matt: Yes, I think that's more an interaction than an adverse drug reaction. In fact frankly, the most common adverse drug reaction in hospitals is probably through excess amounts of water, and that's not medically determined, that's the prescription. Vivienne: Let me now come to Anita. So, you talk to patients all the time about pharmacogenomics in your role. You've been very much involved in patient and public involvement groups at the Wolfson Centre for Personalised Medicine in Liverpool. What do patients think about pharmacogenomics? Is it something they welcome? Anita: I think they do welcome pharmacogenomics, especially so with some of the patients who've experienced some of the more serious, life threatening reactions. And so one of our patients has been doing some work with the Academy of Medical Sciences, and she presented to the Sir Colin Dollery lecture in 2022, and she shared her story of having an adverse drug reaction and the importance of pharmacogenomics, and the impact that pharmacogenomics can have on patient care. Vivienne: Now, I think that was Stevens-Johnson syndrome. We're going to hear in a moment from somebody who did experience Stevens-Johnson's, but just tell us briefly what that is. Anita: Stevens-Johnson syndrome is a potentially life threatening reaction that can be caused by a viral infection, but is more commonly caused by a medicine. There are certain groups of medicines that can cause this reaction, such as antibiotics or anticonvulsants, nonsteroidal anti-inflammatories, and also a drug called allopurinol, which is used to treat gout. Patients have really serious side effects to this condition, and they're often left with long-term health complications. The morbidity and mortality is considerable as well, and patients often spend a lot of time in hospital and take a long time to recover. Vivienne: And let's now hear from Jane Burns for someone with lived experience of that Stevens-Johnson syndrome. When Jane Burns was 19, the medicine she took for her epilepsy was changed. Jane: I remember waking up and feeling really hot, and I was hallucinating, so I was taken to the Royal Liverpool Hospital emergency department by my parents. When I reached A&E, I had a temperature of 40 degrees Celsius. I was given Piriton and paracetamol, and the dermatologist was contacted. My mum had taken my medication to hospital and explained the changeover process with my epilepsy medication. A decision was made to discontinue the Tegretol and I was kept in for observation. Quite rapidly, the rash was changing. Blisters were forming all over my body, my mouth was sore and my jaw ached. My temperature remained very high. It was at this point that Stevens-Johnson syndrome, or SJS, was diagnosed. Over the next few days, my condition deteriorated rapidly. The rash became deeper in colour. Some of the blisters had burst, but some got larger. I developed ulcers on my mouth and it was extremely painful. I started to lose my hair and my fingernails. As I had now lost 65 percent of my skin, a diagnosis of toxic epidermal necrolysis, or TEN, was made. Survivors of SJS TEN often suffer with long-term visible physical complications, but it is important to also be aware of the psychological effects, with some patients experiencing post-traumatic stress disorder. It's only as I get older that I realise how extremely lucky I am to have survived. Due to medical and nursing expertise, and the research being conducted at the time, my SJS was diagnosed quickly and the medication stopped. This undoubtedly saved my life. Vivienne: Now, you've been looking at the development of a passport in collaborating with the AMS and the MHRA. Tell me a bit more about that. Anita: Yes, we set up a patient group at the Wolfson Centre for Personalised Medicine approximately 12 years ago, and Professor Sir Munir Pirmohamed and I, we wanted to explore a little bit more about what was important to patients, really to complement all the scientific and clinical research activity within pharmacogenomics. And patients recognised that, alongside the pharmacogenomic testing, they recognised healthcare professionals didn't really have an awareness of such serious reactions like Stevens-Johnson syndrome, and so they said they would benefit from having a My SJS Passport, which is a booklet that can summarise all of the important information about their care post-discharge, and this can then be used to coordinate and manage their long-term healthcare problems post-discharge and beyond. And so this was designed by survivors for survivors, and it was then evaluated as part of my PhD, and the findings from the work suggest that the passport is like the patient's voice, and it really does kind of validate their diagnosis and raises awareness of SJS amongst healthcare professionals. So, really excellent findings from the research, and the patients think it's a wonderful benefit to them. Vivienne: So, it's a bit like a kind of paper version of the bracelet that you sometimes see people wearing that are on steroids, for instance. Anita: It is like that, and it's wonderful because it's a handheld source of valuable information that they can share with healthcare professionals. And this is particularly important if they're admitted in an emergency and they can't speak for themselves. And so the passport has all that valuable information, so that patients aren't prescribed that drug again, so it prevents them experiencing a serious adverse drug reaction again. Vivienne: So, Stevens-Johnson, Bill, is a really scary side effect, but what about the day to day benefits of pharmacogenomics for patients? Bill: So, what we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing. And it's not just in terms of side effects. It's in terms of the effectiveness of the medicine. Because if a person is prescribed a medicine that doesn't or isn't going to work for them then it can take them longer to recover, to get onto the right medicine. That can have all sorts of detrimental effects. And so when we're thinking about introducing pharmacogenetics more broadly rather than just on a single drug or a single gene basis, we're thinking about that for common drugs like antidepressants, painkillers, statins, the drugs that GPs are often prescribing on a regular basis to a whole range of patients. Vivienne: So, to go back to you, Anita, we're really talking about dose here, aren't we, whether you need twice the dose or half the dose depending on how quickly your body metabolises that particular medicine. How do patients view that? Anita: Well, the patient in question who presented for the Academy of Medical Sciences, I mean, her take on this was, she thinks pharmacogenetics is wonderful because it will allow doctors and nurses to then prescribe the right drug, but also to adapt the dose accordingly to make sure that they get the best outcome, which provides the maximum benefit while also minimising any potential harm. And so from her perspective, that was one of the real benefits of pharmacogenomics. But she also highlighted about the benefits for future generations, the fear of her son taking the same medicine and experiencing the same reaction. And so I think her concerns were, if we have pharmacogenetic testing for a panel of medicines, as Bill mentioned then, then perhaps this would be fantastic for our children as they grow up, and we can identify and predict and prevent these type of reactions happening to future generations. Vivienne: And some of these drugs, Bill, are really very common indeed, something like codeine. Just tell us about codeine, ‘cos it's something – whenever I tell this to friends [laughter], they're always completely entranced by the idea that some people don't need nearly as much codeine as others. Bill: Yeah, so codeine is a drug that's very commonly used as a painkiller. To have its real effect, it needs to be converted in the body to a different drug called morphine, and that is done by an enzyme which is made by a gene called CYP2D6. And we all carry changes in CYP2D6, and the frequency of those variants, whether they make the gene work too much or whether they make it work too little, they vary enormously across the world, so that if you go to parts of Africa, about 30 percent of the population will make more of the CYP2D6, and so they will convert the codeine much more quickly, whereas if you go to the UK, maybe up to ten percent of the white population in the UK just won't be converting codeine to morphine at all, so they won't get any benefit from the drug. So at both ends, you have some people that don't respond and some people that respond a little bit too much so that they need either an alternative drug or they need a different dose. Vivienne: So, all those people who say, you know, “My headache hasn't been touched by this painkiller,” and we say, “What a wimp you're being,” actually, it's to do with genetics. Bill: Yeah, absolutely. There's a biological reason why people don't – not for everybody, but for a significant number of people, that's absolutely right, and we can be far more tailored in how we prescribe medication, and get people onto painkillers that work for them much more quickly. Vivienne: And that's so interesting that it varies by where you come from in the world, because that means we need to give particular attention – and I'm thinking, Anita, to working with patients from different community groups, to make sure that they understand the need for pharmacogenomics. Anita: I think that's really important, Vivienne, and I think we are now having discussions with the likes of Canada SJS awareness group, and also people have been in touch with me from South Africa because people have requested the passport now to be used in different countries, because they think it's a wonderful tool, and it's about raising awareness of pharmacogenomics and the potential benefits of that, and being able to share the tools that we've got to help patients once they've experienced a serious reaction. Vivienne: So, pharmacogenomics clearly is important in the prevention of adverse drug reactions, better and more accurate prescribing, reduced medicines wastage. Does this mean that it's also going to save money, Bill, for the NHS? Bill: Potentially. It should do if it's applied properly, but there's lots of work to make sure that not only are we using the right evidence and using the right types of tests in the laboratory, but we're getting the information to prescribers, so to GPs, to pharmacists, to hospital doctors, in a way that is understandable and meaningful, such that they can then act upon that information. So, the money will only be saved and then can be reused for healthcare if the whole process and the whole pathway works, and that information is used effectively. Vivienne: So, a lot of research to make sure that all of that is in place, and to demonstrate the potential cost savings. Bill: Yes. I mean, there are very nice studies that have been done already in parts of the world that have shown that the savings that could be accrued for applying pharmacogenetics across common conditions like depression, like in patients to prevent secondary types of strokes, are enormous. They run into hundreds of millions of pounds or dollars. But there is an initial investment that is required to make sure that we have the testing in place, that we have the digital pathways to move the information in place, and that there's the education and training, so that health professionals know how to use the information. But the potential is absolutely enormous. Vivienne: Matt, can I turn now to the yellow card. So, people will be very familiar with the yellow card system. So, if you have an adverse reaction, you can send a yellow card in – I mean, literally, it is a yellow card [laughter]. It does exactly what it says on the tin. You send a yellow card to the MHRA, and they note if there's been an adverse effect of a particular medicine. But Genomics England is teaming up with the MHRA to do something more with yellow cards, and we're also doing this with the Yellow Card Biobank. Tell us a bit more. Matt: So, yellow card's a great scheme that was set up decades ago, initially starting off, as you said, with literally yellow cards, but now actually most submissions actually come online. And it's important to note that submissions can come not just from healthcare providers, but majority of submissions actually come from patients themselves, and that people should feel free, if they feel they've had an adverse drug reaction, to report that themselves rather than necessarily depending on a medical practitioner or the healthcare provider to create that report. So, Genomics England is partnering with the MHRA in building what's called the Yellow Card Biobank, the goal of which is to identify genetic markers for adverse drug reactions earlier than has occurred in the past, so that we can then introduce genetic tests to prevent these adverse drug reactions much sooner than has occurred previously. So, what we're doing is basically at the moment we're doing a pilot, but the ultimate plan is that in future, patients who report a serious adverse drug reaction through the Yellow Card Biobank will be asked to provide a sample, a blood sample, that we then screen. We do a whole genome sequence on it, and then combine these with patients who've had like adverse drug reactions and identify genetic markers for that adverse drug reaction medication earlier, that can then be introduced into clinical practice earlier. And this should reduce by decades the amount of time between when adverse drug reactions first start occurring with medications and us then being able to translate that into a preventative mechanism. Vivienne: And will that scheme discover, do you think, new interactions that you didn't know about before? Or do you expect it to turn up what you already know about? Matt: No, I really think there's a lot of discovery that is yet to happen here. In particular, even for drugs that we know cause adverse drug reactions, mostly they've only been studied in people of European ancestry and often in East Asian ancestry, but in many other ancestries that are really important in the global population and in the UK population, like African ancestry and South Asian ancestries, we have very little data. And even within Africa, which is an area which is genetically diverse as the rest of the world put together, we really don't know what different ethnicities within Africa, actually what their genetic background is with regard to adverse drug reactions. The other thing I'd say is that there are a lot of new medications which have simply not been studied well enough. And lastly, that at the moment people are focused on adverse drug reactions being due to single genetic variants, when we know from the model of most human diseases that most human diseases are actually caused by combinations of genetic variants interacting with one another, so-called common disease type genetics, and that probably is similarly important with regard to pharmacogenomics as it is to overall human diseases. That is, it's far more common that these are actually due to common variants interacting with one another rather than the rare variants that we've been studying to date. Vivienne: So, it's a kind of cocktail effect, if you like. You know, you need lots of genes working together and that will produce a reaction that you may not have expected if you'd looked at a single gene alone. Matt: That's absolutely correct, and there's an increasing amount of evidence to show that that is the case with medications, but it's really very early days for research in that field. And the Yellow Card Biobank will be one of many approaches that will discover these genetic variants in years to come. Vivienne: Now, Matt's a research scientist. Bill, you're on the frontline in the NHS. How quickly can this sort of finding be translated into care for people in the NHS? Bill: So, really quickly is the simple answer to that, Viv. If we look at examples from a number of years ago, there's a drug called azathioprine that Matt has used lots in some of his patients. In rheumatology, it's used for patients with inflammatory bowel disease. And the first studies that showed that there was a gene that was relevant to having bad reactions to that drug came out in the 1980s, but it wasn't until well into this century, so probably 30-plus years later that we were routinely using that test in clinical medicine. So, there was an enormous lot of hesitancy about adopting that type of testing, and a bit of uncertainty. If you move forward to work that our colleague Munir Pirmohamed in Liverpool has done with colleagues in Australia like Simon Mallal around HIV medicine, there was this discovery that a drug called abacavir, that if you carried a particular genetic change, that you had a much higher risk of having a really severe reaction to that. The adoption from the initial discovery to routine, worldwide testing happened within four years. So, already we've seen a significant change in the appetite to move quickly to adopt this type of testing, and I see certainly within the NHS and within other health systems around the world, a real desire to adopt pharmacogenetics into routine clinical practice quickly and at scale, but also as part of a broader package of care, which doesn't just solely focus on genetics, but thinks about all the other parts that are important in how we respond to medication. So, making sure we're not on unusual combinations of drugs, or that we're taking our medicine at the right time and with food or not with food, and all of those other things that are really important. And if you link that to the pharmacogenetics, we're going to have a much safer, more effective medicines world. Vivienne: I think one of the joys of working at Genomics England is that you see some of this work really going into clinical practice very fast indeed. And I should say actually that the Wolfson Centre for Personalised Medicine, the PPI group that Anita looks after so well, they've been very important in recruiting people to Yellow Card Biobank. And if anyone's listening to this, Matt, and wants to be part of this, how do they get involved? Or is it simply through the yellow card? Matt: So at the moment, the Yellow Card Biobank is focusing on alopurinol. Vivienne: So, that's a medicine you take for gout. Matt: Which I use a lot in my rheumatology clinical practice. And direct acting oral anticoagulants, DOACs, which are used for vascular disease therapies and haemorrhage as a result of that. So, the contact details are available through the MHRA website, but I think more importantly, it's just that people be aware of the yellow card system itself, and that if they do experience adverse drug reactions, that they do actually complete a report form, ‘cos I think still actually a lot of adverse drug reactions go unreported. Vivienne: I'm forgetting of course that we see Matt all the time in the Genomics England office and we don't think that he has any other home [laughter] than Genomics England, but of course he still sees some patients in rheumatology clinic. So, I want to now look to the future. I mean, I'm, as you both know, a huge enthusiast for pharmacogenomics, ‘cos it's the thing that actually, when you talk to patients or just the general public, they just get it straight away. They can't think why, if you knew about pharmacogenomics, why you wouldn't want to do it. But it's not necessarily an easy thing to do. How can we move in the future, Bill, to a more proactive approach for pharmacogenomics testing? Where would we start? Bill: Yes, so I think we've built up really good confidence that pharmacogenetics is a good thing to be doing. Currently, we're doing that predominantly at the point when a patient needs a particular medicine. That's the time that you would think about doing a genetic test. And previously, that genetic test would only be relevant for that specific drug. I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record. That's what we'd call pre-emptive pharmacogenetic testing, and I think that's the golden land that we want to reach. Vivienne: So for instance, I might have it on my NHS app, and when I go to a doctor and they prescribe something, I show my app to the GP, or something pops up on the GP's screen, or maybe it's something that pops up on the pharmacist's screen. Bill: I think that's right. I think that's what we're looking to get to that point. We know that colleagues in the Netherlands have made some great progress at developing pathways around that. There's a lot of public support for that. And pharmacists are very engaged in that. In the UK, the pharmacists, over the last few years, have really taken a very active role to really push forward this area of medicine, and this should be seen as something that is relevant to all people, and all health professionals should be engaged with it. Vivienne: And on a scale of one to ten, how difficult is it going to be to implement in the NHS? Bill: So, that's a difficult question. I think the first thing is identifying what the challenges are. So I have not given you a number, I've turned into a politician, not answered the question. So, I think what has happened over the last few years, and some of our work within the NHS Network of Excellence in pharmacogenetics and some of the other programmes of work that have been going on, is a really good, honest look at what it is we need to do to try to achieve pharmacogenetics implementation and routine use. I don't think the challenge is going to be predominantly in the laboratory. I think we've got phenomenal laboratories. I think we've got great people doing great genetic testing. I think the biggest challenges are going to be about how you present the data, and that data is accessible. And then ensuring that health professionals really feel that this is information that isn't getting in the way of their clinical practice, but really making a difference and enhancing it, and of benefit both to the healthcare system but more importantly to the patients. Vivienne: Now, when I hear you both talk, my mind turns to drug discovery and research, and Matt, I'm quite sure that that's right at the top of your mind. Tell us how pharmacogenomics can help in drug discovery and research. Matt: So, pharmacogenomics, I think actually just genetic profiling of diseases in itself just to start off with is actually a really good way of identifying new potential therapeutic targets, and also from derisking drug development programmes by highlighting likely adverse drug reactions of medications that are being considered for therapeutic trials, or targets that are being considered for therapeutic development. Pharmacogenomics beyond that is actually largely about – well, it enables drug development programmes by enabling you to target people who are more likely to respond, and avoid people who are more likely to have adverse drug reactions. And so that therapeutic index of the balance between likely efficacy versus likely toxicity, genetics can really play into that and enable medications to be used where otherwise they might have failed. This is most apparent I think in the cancer world. A classic example there, for example, is the development of a class of medications called EGFR inhibitors, which were developed for lung cancer, and in the initial cancer trials, actually were demonstrated to be ineffective, until people trialled them in East Asia and found that they were effective, and that that turns out to be because the type of cancers that respond to them are those that have mutations in the EGFR gene, and that that's common in East Asians. We now know that, wherever you are in the world, whether you're East Asian or European or whatever, if you have a lung adenocarcinoma with an EGFR mutation, you're very likely to respond to these medications. And so that pharmacogenomic discovery basically rescued a class of medication which is now probably the most widely used medication for lung adenocarcinomas, so a huge beneficial effect. And that example is repeated across multiple different cancer types, cancer medication types, and I'm sure in other fields we'll see that with expansive new medications coming in for molecularly targeted therapies in particular. Vivienne: So, smaller and more effective trials rather than larger trials that perhaps seem not to work but actually haven't been tailored enough to the patients that are most likely to benefit. Matt: Yeah, well, particularly now that drug development programmes tend to be very targeted at specific genetic targets, pharmacogenetics is much more likely to play a role in identifying patients who are going to respond to those medications. So, I think many people in the drug development world would like to see that, for any significant drug development programme, there's a proper associated pharmacogenomic programme to come up with molecular markers predicting a response. Vivienne: We're going to wrap up there. Thank you so much to our guests, Bill Newman, Anita Hanson, Matt Brown, and our patient Jane Burns. Thank you so much for joining us today to discuss pharmacogenomics in personalised medicine, and the benefits, the challenges and the future prospects for integrating pharmacogenomics into healthcare systems. And if you'd like to hear more podcasts like this, please subscribe to Behind the Genes. It's on your favourite podcast app. Thank you so much for listening. I've been your host, Vivienne Parry. This podcast was edited by Bill Griffin at Ventoux Digital and produced by the wonderful Naimah. Bye for now.

The Condition of the Human Heart - Bill Newman (Evangelist) 13 August 2024

australia condition evangelist human heart bill newman

Play Episode Listen Later Aug 13, 2024 45:34

The Condition of the Human HeartYour support sends the gospel to every corner of Australia through broadcast, online and print media: https://vision.org.au/donateSee omnystudio.com/listener for privacy information.

JFK (1991) ZO RICHARDSON OF "LOOK BACK CINEMA-THE PODCAST" JOINED HODGEPOD TO TALK OF THIS MOVIE DIRECTED BY OLIVER STONE-EPISODE 79

HODGEPOD with Rob Fredette

Play Episode Listen Later Jul 8, 2024 64:58

Zo Richardson of Look Back Cinema-The Podcast joined HODGEPOD to talk the movie JFK directed by Oliver Stone and starring Kevin Costner as the lead actor. This movie had an all star lineup of actors. Kevin Costner (Jim Garrison), Tommy Lee Jones( Clay Shaw) , Joe Pesci (David Ferrie), Kevin Bacon( Willie O'Keefe), John Candy(Dean Anderson), Jack Lemmon(Jack Martin), Walter Matthau ( Senator Long), Vincent D'nofrio( Bill Newman) , Sissy Spacek(Liz Garrison) , Michael Rooker (Bill Broussard) Wayne Knight (Numa Bertel), Gary Oldham ( Lee Harvey Oswald), Donald Sutherland(Mr. X) ,Jay O Sanders ( Lou Ivon). Some of these actors were in roles we were ands are not accustomed to seeing and this made the movie extraodinary. Rob and Zo covered: -The reaction to the movie in 1991 -Tremendous scenes explaining Jim Garrison's struggles -How this movie still resonates today. -The cast and some of the characters. Kevin Costner, Tommy Lee Jones and Joe Pesci. -Oliver Stone's different look at the JFK assassination off the Warren Commission. RECORDED JUNE 19, 2024. Please give a listen on these apps, APPLE, SPOTIFY, IHEART, AUDACY, TUNE IN AND THE PODBEAN APP. Please give a follow and a rating. Email hodgepodallin@yahoo.com.

spotify movies apple cinema john f kennedy directed richardson zo kevin costner iheart oliver stone tremendous joe pesci tommy lee jones warren commission vincent d jim garrison bill newman

JFK (1991) ZO RICHARDSON OF "LOOK BACK CINEMA-THE PODCAST" JOINED HODGEPOD TO TALK OF THIS MOVIE DIRECTED BY OLIVER STONE-EPISODE 79

HODGEPOD with Rob Fredette

Play Episode Listen Later Jul 8, 2024 64:58

Zo Richardson of Look Back Cinema-The Podcast joined HODGEPOD to talk the movie JFK directed by Oliver Stone and starring Kevin Costner as the lead actor. This movie had an all star lineup of actors. Kevin Costner (Jim Garrison), Tommy Lee Jones( Clay Shaw) , Joe Pesci (David Ferrie), Kevin Bacon( Willie O'Keefe), John Candy(Dean Anderson), Jack Lemmon(Jack Martin), Walter Matthau ( Senator Long), Vincent D'nofrio( Bill Newman) , Sissy Spacek(Liz Garrison) , Michael Rooker (Bill Broussard) Wayne Knight (Numa Bertel), Gary Oldham ( Lee Harvey Oswald), Donald Sutherland(Mr. X) ,Jay O Sanders ( Lou Ivon). Some of these actors were in roles we were ands are not accustomed to seeing and this made the movie extraodinary. Rob and Zo covered: -The reaction to the movie in 1991 -Tremendous scenes explaining Jim Garrison's struggles -How this movie still resonates today. -The cast and some of the characters. Kevin Costner, Tommy Lee Jones and Joe Pesci. -Oliver Stone's different look at the JFK assassination off the Warren Commission. RECORDED JUNE 19, 2024. Please give a listen on these apps, APPLE, SPOTIFY, IHEART, AUDACY, TUNE IN AND THE PODBEAN APP. Please give a follow and a rating. Email hodgepodallin@yahoo.com.

spotify movies apple cinema john f kennedy directed richardson zo kevin costner iheart oliver stone tremendous joe pesci tommy lee jones warren commission vincent d jim garrison bill newman

The Rapture

Rapture on SermonAudio

Play Episode Listen Later Mar 3, 2024 52:00

A new MP3 sermon from Thornlands Bible Church is now available on SermonAudio with the following details: Title: The Rapture Speaker: Bill Newman Broadcaster: Thornlands Bible Church Event: Sunday Service Date: 3/3/2024 Bible: 1 Thessalonians 4:13-18; 1 Corinthians 15:52 Length: 52 min.

bible speaker event corinthians thessalonians rapture broadcaster sunday service sermonaudio bill newman

January Jones - JFK Expert -The Man From 2063 by Jack Duffy

January Jones sharing Success Stories

Play Episode Listen Later Feb 22, 2024 53:00

Author of The Man From 2063, is an expert on the assassination of President Kennedy. He became interested in the JFK assassination after seeing a bootleg copy of the famous Zapruder filmof President Kennedy's fatal motorcade in 1972. He has been researching the assassination ever since. Jack's entertaining book draws on his deep knowledge and personal research into the President's murderand is therefore based on actual events and people surrounding the assassination. Jack has interviewed many key eyewitnesses to the assassination of President John Kennedy, including Buell Frazier, Jean Hill, Mary Moorman, Beverly Oliver, and Bill Newman. He has also interviewed 2 surgeons who treated JFK at Parkland hospital - Dr. Robert McClelland and Dr. Charles Crenshaw. He has interviewed Marina Oswald. Jack has also met many researchers who have written books on the assassination including Vincent Bugliosi, Mark Lane, Josiah Thompson, Robert Groden, Jim Marrs and Gaeton Fonzi. MUST READ THE MAN FROM 2063 JACK DUFFY

women president success conspiracies john f kennedy assassination parkland john kennedy zapruder january jones mark lane jim marrs vincent bugliosi bill newman jack duffy jean hill beverly oliver

Civil Politics (1/19/24): Bill of Opinions

Civil Politics

Play Episode Listen Later Jan 20, 2024 58:17

Tonight we welcomed Bill Newman and Dan Torres Co-host and producer of the WHMP show on Talk the Talk! Further Reading:How Donald Trump Answers A Question - LINK (Youtube)How Bernie Sanders Answers A Question - LINK (Youtube) Remember to Register to vote! Mass Residents should go to: https://www.sec.state.ma.us/ele/For more Civil Politics visit our website, civilpoliticsradio.com!Don't miss another episode - subscribe to our podcast (iTunes, Google Play, Spotify, and more!)Support Civil Politics by donating to the tip jar: https://tips.pinecast.com/jar/civilpoliticsradioThis podcast is a member of the Planetside Podcast Network. Visit PlanetsidePodcasts.com to find other Planetside Productions!Send us your feedback online: https://pinecast.com/feedback/civilpoliticsradio/68f6cbbb-26a1-49a1-a930-5c570fda1d89

spotify politics talk register google play civil bill newman planetside podcast network planetside productions

Rants & rAVes Episode 1285: The Best Webinar of 2023 Will Be My ‘What Mattered in 2023' Panel on December 13

Rants & rAVes

Play Episode Listen Later Dec 5, 2023 8:25

In the most anticipated panel of 2023, a panel of AV, UCC and Digital Signage experts will join me to explore what of 2023 will affect 2024 and beyond. The panel of experts will review key trends, newly debuted technologies and discuss how to prepare for the upcoming year, as many of these experts have insights into what's to come in ProAV, digital signage and UCC. To prep us for the webinar, Yealink's senior sales engineer, Bill Newman, joined me on this episode of Rants & rAVes to talk about one of the products that debuted in 2023 that will steer 2024: the MVC S90. By the way: The webinar is free and approved for 1.0 CTS, CTS-D or AVIXA CTS-I RUs.

panel webinars rants av raves ucc cts digital signage rants raves pro av bill newman

Checking the Spiritual Pulse of Australia - Bill Newman (Evangelist) 7 Aug 2023

australia spiritual checking pulse evangelist bill newman

Play Episode Listen Later Aug 7, 2023 45:44

Australia’s Best-Known Evangelist Bill Newman Updates us on Recent HappeningsHelp Vision to keep 'Connecting Faith to Life': https://vision.org.au/donateSee omnystudio.com/listener for privacy information.

EXTRA: Who Is The Hustler Files (Interview on Talk the Talk)

talk files hustlers talk the talk bill newman

Play Episode Listen Later Jun 28, 2023 19:26

Each morning, from 9am-11am, Bill Newman and Buz Eisenberg host Talk the Talk radio show on WHMP. In this EXTRA episode of The Hustler Files, Creator/Host Lisa Reilly has the opportunity to share how The Hustler Files came to be and why it's such a passion project.

How Canada Can Build An Auto Industry of the Future

TheFutureEconomy.ca Podcast

Play Episode Listen Later Jun 23, 2023 35:06

What will the future of Canada's auto industry look like? What are the biggest challenges we face in building this sector up and what can we do to accelerate innovation and ensure competitiveness? Bill Newman, Chief Industry Executive Advisor, Automotive and Manufacturing for SAP, shares his perspective on the Canadian auto industry in this new interview.

canada canadian manufacturing sap automotive auto industry bill newman

The Evolution of Fonts on Computers

The History of Computing

Play Episode Listen Later Apr 10, 2023 20:04

Gutenburg shipped the first working printing press around 1450 and typeface was born. Before then most books were hand written, often in blackletter calligraphy. And they were expensive. The next few decades saw Nicolas Jensen develop the Roman typeface, Aldus Manutius and Francesco Griffo create the first italic typeface. This represented a period where people were experimenting with making type that would save space. The 1700s saw the start of a focus on readability. William Caslon created the Old Style typeface in 1734. John Baskerville developed Transitional typefaces in 1757. And Firmin Didot and Giambattista Bodoni created two typefaces that would become the modern family of Serif. Then slab Serif, which we now call Antique, came in 1815 ushering in an era of experimenting with using type for larger formats, suitable for advertisements in various printed materials. These were necessary as more presses were printing more books and made possible by new levels of precision in the metal-casting. People started experimenting with various forms of typewriters in the mid-1860s and by the 1920s we got Frederic Goudy, the first real full-time type designer. Before him, it was part of a job. After him, it was a job. And we still use some of the typefaces he crafted, like Copperplate Gothic. And we saw an explosion of new fonts like Times New Roman in 1931. At the time, most typewriters used typefaces on the end of a metal shaft. Hit a kit, the shaft hammers onto a strip of ink and leaves a letter on the page. Kerning, or the space between characters, and letter placement were often there to reduce the chance that those metal hammers jammed. And replacing a font would have meant replacing tons of precision parts. Then came the IBM Selectric typewriter in 1961. Here we saw precision parts that put all those letters on a ball. Hit a key, the ball rotates and presses the ink onto the paper. And the ball could be replaced. A single document could now have multiple fonts without a ton of work. Xerox exploded that same year with the Xerox 914, one of the most successful products of all time. Now, we could type amazing documents with multiple fonts in the same document quickly - and photocopy them. And some of the numbers on those fancy documents were being spat out by those fancy computers, with their tubes. But as computers became transistorized heading into the 60s, it was only a matter of time before we put fonts on computer screens. Here, we initially used bitmaps to render letters onto a screen. By bitmap we mean that a series, or an array of pixels on a screen is a map of bits and where each should be displayed on a screen. We used to call these raster fonts, but the drawback was that to make characters bigger, we needed a whole new map of bits. To go to a bigger screen, we probably needed a whole new map of bits. As people thought about things like bold, underline, italics, guess what - also a new file. But through the 50s, transistor counts weren't nearly high enough to do something different than bitmaps as they rendered very quickly and you know, displays weren't very high quality so who could tell the difference anyways. Whirlwind was the first computer to project real-time graphics on the screen and the characters were simple blocky letters. But as the resolution of screens and the speed of interactivity increased, so did what was possible with drawing glyphs on screens. Rudolf Hell was a German, experimenting with using cathode ray tubes to project a CRT image onto paper that was photosensitive and thus print using CRT. He designed a simple font called Digital Grotesk, in 1968. It looked good on the CRT and the paper. And so that font would not only be used to digitize typesetting, loosely based on Neuzeit Book. And we quickly realized bitmaps weren't efficient to draw fonts to screen and by 1974 moved to outline, or vector, fonts. Here a Bézier curve was drawn onto the screen using an algorithm that created the character, or glyph using an outline and then filling in the space between. These took up less memory and so drew on the screen faster. Those could be defined in an operating system, and were used not only to draw characters but also by some game designers to draw entire screens of information by defining a character as a block and so taking up less memory to do graphics. These were scalable and by 1979 another German, Peter Karow, used spline algorithms wrote Ikarus, software that allowed a person to draw a shape on a screen and rasterize that. Now we could graphically create fonts that were scalable. In the meantime, the team at Xerox PARC had been experimenting with different ways to send pages of content to the first laser printers. Bob Sproull and Bill Newman created the Press format for the Star. But this wasn't incredibly flexible like what Karow would create. John Gaffney who was working with Ivan Sutherland at Evans & Sutherland, had been working with John Warnock on an interpreter that could pull information from a database of graphics. When he went to Xerox, he teamed up with Martin Newell to create J&M, which harnessed the latest chips to process graphics and character type onto printers. As it progressed, they renamed it to Interpress. Chuck Geschke started the Imaging Sciences Laboratory at Xerox PARC and eventually left Xerox with Warnock to start a company called Adobe in Warnock's garage, which they named after a creek behind his house. Bill Paxton had worked on “The Mother of All Demos” with Doug Engelbart at Stanford, where he got his PhD and then moved to Xerox PARC. There he worked on bitmap displays, laser printers, and GUIs - and so he joined Adobe as a co-founder in 1983 and worked on the font algorithms and helped ship a page description language, along with Chuck Geschke, Doug Brotz, and Ed Taft. Steve Jobs tried to buy Adobe in 1982 for $5 million. But instead they sold him just shy of 20% of the company and got a five-year license for PostScript. This allowed them to focus on making the PostScript language more extensible, and creating the Type 1 fonts. These had 2 parts. One that was a set of bit maps And another that was a font file that could be used to send the font to a device. We see this time and time again. The simpler an interface and the more down-market the science gets, the faster we see innovative industries come out of the work done. There were lots of fonts by now. The original 1984 Mac saw Susan Kare work with Jobs and others to ship a bunch of fonts named after cities like Chicago and San Francisco. She would design the fonts on paper and then conjure up the hex (that's hexadecimal) for graphics and fonts. She would then manually type the hexadecimal notation for each letter of each font. Previously, custom fonts were reserved for high end marketing and industrial designers. Apple considered licensing existing fonts but decided to go their own route. She painstakingly created new fonts and gave them the names of towns along train stops around Philadelphia where she grew up. Steve Jobs went for the city approach but insisted they be cool cities. And so the Chicago, Monaco, New York, Cairo, Toronto, Venice, Geneva, and Los Angeles fonts were born - with her personally developing Geneva, Chicago, and Cairo. And she did it in 9 x 7. I can still remember the magic of sitting down at a computer with a graphical interface for the first time. I remember opening MacPaint and changing between the fonts, marveling at the typefaces. I'd certainly seen different fonts in books. But never had I made a document and been able to set my own typeface! Not only that they could be in italics, outline, and bold. Those were all her. And she inspired a whole generation of innovation. Here, we see a clean line from Ivan Sutherland and the pioneering work done at MIT to the University of Utah to Stanford through the oNLine System (or NLS) to Xerox PARC and then to Apple. But with the rise of Windows and other graphical operating systems. As Apple's 5 year license for PostScript came and went they started developing their own font standard as a competitor to Adobe, which they called TrueType. Here we saw Times Roman, Courier, and symbols that could replace the PostScript fonts and updating to Geneva, Monaco, and others. They may not have gotten along with Microsoft, but they licensed TrueType to them nonetheless to make sure it was more widely adopted. And in exchange they got a license for TrueImage, which was a page description language that was compatible with PostScript. Given how high resolution screens had gotten it was time for the birth of anti-aliasing. He we could clean up the blocky “jaggies” as the gamers call them. Vertical and horizontal lines in the 8-bit era looked fine but distorted at higher resolutions and so spatial anti-aliasing and then post-processing anti-aliasing was born. By the 90s, Adobe was looking for the answer to TrueImage. So 1993 brought us PDF, now an international standard in ISO 32000-1:2008. But PDF Reader and other tools were good to Adobe for many years, along with Illustrator and then Photoshop and then the other products in the Adobe portfolio. By this time, even though Steve Jobs was gone, Apple was hard at work on new font technology that resulted in Apple Advanced Typography, or AAT. AAT gave us ligature control, better kerning and the ability to write characters on different axes. But even though Jobs was gone, negotiations between Apple and Microsoft broke down to license AAT to Microsoft. They were bitter competitors and Windows 95 wasn't even out yet. So Microsoft started work on OpenType, their own font standardized language in 1994 and Adobe joined the project to ship the next generation in 1997. And that would evolve into an open standard by the mid-2000s. And once an open standard, sometimes the de facto standard as opposed to those that need to be licensed. By then the web had become a thing. Early browsers and the wars between them to increment features meant developers had to build and test on potentially 4 or 5 different computers and often be frustrated by the results. So the WC3 began standardizing how a lot of elements worked in Extensible Markup Language, or XML. Images, layouts, colors, even fonts. SVGs are XML-based vector image. In other words the browser interprets a language that displays the image. That became a way to render Web Open Format or WOFF 1 was published in 2009 with contributions by Dutch educator Erik van Blokland, Jonathan Kew, and Tal Leming. This built on the CSS font styling rules that had shipped in Internet Explorer 4 and would slowly be added to every browser shipped, including Firefox since 3.6, Chrome since 6.0, Internet Explorer since 9, and Apple's Safari since 5.1. Then WOFF 2 added Brotli compression to get sizes down and render faster. WOFF has been a part of the W3C open web standard since 2011. Out of Apple's TrueType came TrueType GX, which added variable fonts. Here, a single font file could contain a number or range of variants to the initial font. So a family of fonts could be in a single file. OpenType added variable fonts in 2016, with Apple, Microsoft, and Google all announcing support. And of course the company that had been there since the beginning, Adobe, jumped on board as well. Fewer font files, faster page loads. So here we've looked at the progression of fonts from the printing press, becoming more efficient to conserve paper, through the advent of the electronic typewriter to the early bitmap fonts for screens to the vectorization led by Adobe into the Mac then Windows. We also see rethinking the font entirely so multiple scripts and character sets and axes can be represented and rendered efficiently. I am now converting all my user names into pig Latin for maximum security. Luckily those are character sets that are pretty widely supported. The ability to add color to pig Latin means that OpenType-SVG will allow me add spiffy color to my glyphs. It makes us wonder what's next for fonts. Maybe being able to design our own, or more to the point, customize those developed by others to make them our own. We didn't touch on emoji yet. But we'll just have to save the evolution of character sets and emoji for another day. In the meantime, let's think on the fact that fonts are such a big deal because Steve Jobs took a caligraphy class from a Trappist monk named Robert Palladino while enrolled at Reed College. Today we can painstakingly choose just the right font with just the right meaning because Palladino left the monastic life to marry and have a son. He taught jobs about serif and san serif and kerning and the art of typography. That style and attention to detail was one aspect of the original Mac that taught the world that computers could have style and grace as well. It's not hard to imagine if entire computers still only supported one font or even one font per document. Palladino never owned or used a computer though. His influence can be felt through the influence his pupil Jobs had. And it's actually amazing how many people who had such dramatic impacts on computing never really used one. Because so many smaller evolutions came after them. What evolutions do we see on the horizon today? And how many who put a snippet of code on a service like GitHub may never know the impact they have on so many?

new york university chicago google apple los angeles mother san francisco phd philadelphia evolution toronto german microsoft mit utah jobs press mac computers stanford dutch latin windows steve jobs images venice adobe monaco safari chrome vertical photoshop illustrator github iso crt firefox css whirlwind bill paxton xerox antique courier warnock times new roman transitional jm internet explorer fonts postscript trappist xml reed college w3c palladino guis old style nls aat ikarus xerox parc serif svgs blokland kerning karow woff john warnock susan kare all demos martin newell wc3 bill newman doug engelbart gutenburg online system ivan sutherland opentype macpaint truetype john baskerville jonathan kew

BamBox Devil's Reign: X-men #1 signed by Vincent D'onofrio unbox and review

Talk Nerdy to Me

Play Episode Listen Later Apr 1, 2023 5:53

I received an email from BamBox saying they were moving offices and found some stuff that had been stashed away and forgotten until they started packing up. One of those items was Devil's Reign: X-men #1 signed and CGC witnessed by Vincent D'onofrio. Devil's Reign is a good story-line from Marvel that centers on Daredevil/Kingpin, but it does crossover to a few other titles (like X-men). The gist of the story is Wilson Fisk aka Kingpin is mayor of NYC. He decides he wants to get rid of all those pesky mutants. How the X-men tie into it is Kingpin wants to get rid of the Krakoan tree portal the X-men have in NYC. There is a fair bit of Emma Frost flexing, Daredevil & Elektra fighting, and a smidgen of Purple Man added to make things interesting. The story alone wasn't enough to make me want to buy this slab. The Vincent D'onofrio autograph on that cover with the amazing artwork depicting Kingpin is what sold it for me. Vincent is a very versatile actor who has portrayed many fan favorite characters in movies and TV. Some of his more memorable for me are Private Pyle from Fullmetal Jacket, Bill Newman in JFK, Edgar in Men in Black, Carl Stargher in the Cell, Vic Hosking in Jurassic World, Robert Goren in Law & Order: Criminal Intent, and Wlison Fisk (Kingpin) in the MCU. He brings a little something special to each of these characters. I think if you are a fan of both the X-men and Vincent D'onofrio as I am, this signed slab is an amazing piece. Even if you are just a D'onofrio fan, having his autograph on this comic about one of his most popular characters is a great addition to your collection. If you could care less about Vincent D'onofrio or you don't collect autographs, you would be better served just picking up a raw copy of the comic or an unsigned slab. SUBSCRIBE to watch more videos like this one! LET'S CONNECT! -- Zia Comics website -- Zia Comics TikTok -- Zia Comics Facebook -- Zia Comics Twitter -- Zia Comics Instagram LISTEN TO OUR PODCAST! - iTunes #ziacomics #lascruces #newmexico #bambox #bammer #xmen #daredevil #devilsreign #emmafrost #wilsonfisk #kingpin #elektra #vincentdonofrio #marvel #marvelstudios #marvelcomics #cgc #autographs

tv new york city marvel devil mcu john f kennedy xmen signed men in black jurassic world kingpin cgc unbox emma frost wilson fisk vincent d purple man law order criminal intent krakoan bill newman devil's reign x men bambox

Ep 10: Dealey Plaza Witnesses (Part 2) Did Ed Hoffman Really See The Grassy Knoll Shooter? Did the Railroad Employees See Smoke from the Shots on the Grassy Knoll?

Solving JFK

Play Episode Listen Later Feb 21, 2023 37:53

In this second episode of the series on Dealey Plaza, we look at the witness statements of Ed Hoffman, Tom Tilson, Orville Nix, Bill Newman, James Tague, Lee Bowers and the other Railroad Employees on the overpass (Sam Holland, Richard Dodd, and James Simmons). Follow us on Social Media: Twitter - https://twitter.com/solvingjfk Facebook - https://www.facebook.com/solvingjfk Instagram - https://www.instagram.com/solvingjfkpodcast Tik Tok - https://www.tiktok.com/@solvingjfk Transcripts and Sources - https://www.solvingjfkpodcast.com

tiktok employees smoke shots witnesses shooters railroads dealey plaza grassy knoll james simmons ed hoffman bill newman richard dodd orville nix

Inside Insights: The Evolving Electric Vehicle (EV) Market with William ”Bill” Newman

Play Episode Listen Later Feb 20, 2023 22:53

In this episode of Tech-Driven Business, William ("Bill") Newman, Industry Executive Advisor (Chief), Automotive for the Customer Innovation Office at SAP North America, rejoins Mustansir Saifuddin to talk about the electronic vehicle (EV) market. Bill shares background on the EV market, how the market is developing, and what to expect in the future. From fuel cell technology to point charging to the changing user experience and sustainability, Bill covers a lot. More importantly he shares some valuable information for consumers and suppliers alike. Bill has over 35 years of executive leadership, strategy, consulting, practice management experience balanced with extensive public speaking and higher education experience. A former leadership team member for Volkswagen's IT division, he is the author of two books on enterprise performance and has worked with many OEMs and suppliers across the automotive industry. Connect with Us: LinkedIn: Bill Newman, Mustansir Saifuddin, Innovative Solution Partners Twitter: @william_newman @Mmsaifuddin Instagram @billwine5 YouTube isolutionpartners or learn more about our sponsor Innovative Solution Partners to schedule a free consultation. Episode Transcript [00:00:03.760] - Mustansir Saifuddin Welcome to Tech Driven Business brought to you by Innovative Solution Partners. In this episode, I welcome back Bill Newman of SAP. Listen in as Bill shares a background on the electric vehicles or the EV market. He dives into not only the past, but what we can expect to see down the road for suppliers across industries. [00:00:30.200] - Mustansir Saifuddin Hello, Bill. How are you? [00:00:32.060] - Bill Newman Good, Mustansir. Good to be back on your show. [00:00:35.960] - Mustansir Saifuddin Thank you. Hey, welcome to Tech-Driven Business. We had some interesting conversations in the past and I'd like to continue our talk. But this time I picked a different topic than what we had discussed in the past. So looking forward to having that conversation with you. [00:00:53.120] - Bill Newman Sounds great. Let's dive in. [00:00:56.490] - Mustansir Saifuddin All right. So what we want to discuss as part of the show today is electric vehicles or EV and technology and how they go hand in hand. So with that, let's start with our conversation. I want to start off with, what are some of the cool things on the horizon when you talk about EV market? Can you just give us some background and your perspective on that? [00:01:24.740] - Bill Newman Well, sure. I think listeners will be pretty familiar with the light passenger space. Battery electric vehicles, plug in hybrid electric vehicles, particularly those are going to be some of the things that we're seeing now and will continue to see. In other parts of the vehicle space, we're seeing hydrogen, other aspects of fuel cell technology, particularly for long-haul. But the general consumer, unless they're part of that transportation business, is probably, at least in the near term, not going to be impacted by that. With electrification comes this pesky business of having to charge a vehicle. I think listeners might be aware of the term range anxiety. The good news is that on a couple of fronts, battery density and the ability to charge a battery quickly using a DC direct-current fast-charging methods and even some infrastructure that allows parallel DC fast-charging will become more and more available. So it's not just we need locations for charging, but we also need those locations to be quick, efficient, and effective. People understand that you can't just put charging stations out in a parking lot and it works great in the summertime. But when there's weather and in the Sun Belt, the weather can be in the summertime, you have to also provide a friendly charging environment for that. [00:03:14.240] – Bill Newman So you're going to have covers and maybe some solar collection on the top of the covers, maybe some heated environments for northern climates. These things are all being talked about. We went in deep with them with a recent center of automotive research event that we had that SAP sponsored in San Ramon at the end of 2022. I think also, too, the fact that the federal government is enabling an additional subsidy program for passenger EVs, and also putting some significant infrastructure dollars on the table as a part of the IRA will allow not just the Coast and a lot of the key Gulf Sunbelt strips, which do seem to have a high propensity for charging station density, but allow those to fill into places like in America's heartland where there's lots of open stretches in places where the traditional oil and gas companies have fought to keep electric charging out. So I do think that you'll begin to see over the next few years a little bit less range anxiety. Maybe even we get closer to the mythical 1,000 mile charge, which would really free up EVs as a cross continental and road trip platform that you could take with your friends, your family, maybe even towing, given the fact that we've got some really cool high torque electric vehicle trucks that are now making it into the marketplace and are getting very well received. Here to show everybody around the candy store what might be coming with EVs. So far, it all looks pretty good over the next few years. [00:05:16.620] - Mustansir Saifuddin I think it's a very exciting time that we're living in, especially that some of the changes that are coming in this segment of the market is pretty phenomenal. How the battery life has been standing in a matter of very short period of time. I think this is really exciting stuff. Taking that growth in that EV space now, looking from the lens of a technology company, how can tech companies support this evolving EV market? [00:05:54.100] - Bill Newman Well, staying on the topic of point charging, we see there an emergence of a new role in the auto ecosystem and that of energy provisioner. Being not just the companies that create third-party charging stations, but actually brands owning that as an option to say someone like you or I buying an electric vehicle, just like we would decide that we want some sporty wheels and trim packages on our vehicle. Maybe there's a package for pulling a boat, and we'll also be able to buy a trim package to hang a charging unit on the inside of our garage and be able to charge that way. Those are products that need to be built. Those are products that need to be serviced and managed. Guess what? There's a lot of companies, like all the big brands that want to have a piece of that and not only just white label those to be able to provide to their customers, but also be able to potentially do some fractal billing, a few basis pennies per kilowatt hour over time really adds up. And so there's a significant upside and revenue potential there and the Wall Street Journal covered that pretty extensively in an article in late 2022. [00:07:18.940] - Bill Newman So those are all good things from a vehicle technology perspective, obviously higher density batteries, non-heavy metal batteries. So doing a lot of work with silicone, which can be developed synthetically and not have to be mined and harvested out of tough to reach and sometimes areas with really poor labor practices or maybe not politically friendly to Western markets. So there's a real upside there. And really just also, I think when you look at EVs, the nature, and I've spoken about this on this program and others, the nature of how EVs are shifting the experience from the front-seat driver experience to what I call the back-seat passenger experience, where you might be traveling in a semi-autonomous vehicle that is electrified and may not have a steering wheel, may actually feel more like a rolling, either workplace, or family space. And those provide new opportunities for companies who provide interiors, who provide lighting, who provide sound and instrumentation. We are working with suppliers today, automotive suppliers today, that are really thrilled with the opportunity to come up with some of these new creative designs or creative applications to support some of the new technologies that are going into different EV designs. [00:08:56.580] - Bill Newman That piece is really extraordinary. If you look back in time, it's almost like when we left the Model A and the lifted carriage design that Henry Ford made so popular and really began to go into the longer sedan like driving experience where everybody could go for a Sunday drive in the countryside. And it was really liberating. I think in many ways we're at that next juncture point now in the design of vehicles that EV is letting us aspire to. [00:09:36.600] - Mustansir Saifuddin I like your comparison. Really, it is coming to the point where we are going to see a big shift, at least from the vantage point we are at right now, seems like the possibilities are endless, especially when you talk about the interior of a car and the experience of a passenger, not just a driver. You're bringing in a whole new market segment, not only for organizations who are building those interiors, but technology companies who provide those accessories where it opens up a lot of opportunities for the consumers to have a different experience altogether in a vehicle. [00:10:24.330] - Bill Newman I'll just add really quickly to that and do a shout out to the Experiences Per Mile Advisory Council, and the report that they issued in 2022, actually was the first report of its kind that suggested that the utility or the experience value, the value of an experience was different based on the purpose for that particular use of a vehicle. So if I was going on a vacation road trip, or if I was just driving to the office, or I was taking my kids to a soccer practice, there were lots of different use cases. And it's really pretty extraordinary to see then, are we moving to a place, particularly with new EV design, where we're actually designing or maybe just using a vehicle specifically fit for a given purpose or a set of specific purposes. And then for another basket of reasons why we would use a vehicle, we use something completely different all together. Really suggests a huge differentiation in potentially where vehicles could go and maybe moving out of that, how many hundreds of thousands of this particular vehicle did I produce to make money in a particular year to how personalized was I able to make this vehicle experience to my customers? [00:11:55.840] - Bill Newman And how many times were they able to come into my portfolio of different vehicles to get the value that they wanted? So it's pretty fascinating stuff. [00:12:07.660] - Mustansir Saifuddin I think you touched upon a very important point over here, the experience economy. Everything is about the experience now. This whole EV market can definitely change how folks look at a mode of transportation being so versatile and so open to having these possibilities which were unimaginable a few years back. Definitely a big shift in this direction. On a separate note, let me ask you this, what do you consider your biggest accomplishment? I know on a professional level, definitely you have a lot to share, but something that sticks out to you on a personal professional level that you'd like to share with our listeners? [00:13:01.080] - Bill Newman Well, I think outside of my family, on a personal level professionally, I've always tried to be more of a teacher and a mentor. Interesting story. When I was a junior at UCLA, I was a substitute teacher for a school district that was on strike. All the world of respect to educators out there, but I was a hungry college student that needed to earn a few bucks, so I taught some math classes. One of my most fulfilling moments in my early adulthood was being able to work with some of the high school students that frankly hadn't gotten much of a shot from the institutional educators that were working at the high school that I was pinch hitting in and really being able to watch them grow. I've learned over the years that some of them have actually gone on to become educators themselves. I find that hugely fulfilling and feels like I have in a small way left a mark in somebody's life moving forward. Also just as a youth leader, too, as the same thing, whether it's at church or boy scouts or any of those things. Professionally, I've been part of some really cool vehicle design programs. [00:14:23.900] - Bill Newman Listeners might know that I was an airplane guy before I was an automobile guy. So being able to take advantage of some design to first flight vehicle programs was really rewarding for me, as well as watching the Volkswagen Beatle sunset and roll off the assembly line down in Puebla, Mexico, after owning one as my first car when I had just gotten my license when I was 16. Those are just some fun things that come to mind. Appreciate you asking the question. [00:15:03.360] - Mustansir Saifuddin Now, that's awesome. I can see that spark in your eyes when you talk about teaching and your passion for that and how it relates to your professional life also. But coming back to our topic, when you talk about EVs and this whole conversation about technology, what's your take on sustainability? How big a role is sustainability playing for the supply chain as you have seen in the past year or what do you see as the future in 2023? [00:15:39.080] - Bill Newman Well, for sure, we're doing in our supply chain, we're moving more to a make-to-market, so more of a regionalization, which is good ecologically. Putting things on airplanes and putting them on boats and making them go thousands of miles. Yeah, I understand that there's a factor cost benefit to it to keep the price low, but it's not a good thing in terms of emissions either from vehicles or from ships, air vehicles, airplanes, air cargo jets in particular, and it's also very expensive. So I think that that aside, being able to figure out a way to manufacture EV technologies with less of a reliance on heavy materials that, again, need to be strip mined in many situations and have a tendency to devastate the environment of developing nations and not so developing nations who are doing that at their own expense. I think that there's something to be said about that. We're going to look at Scope 1, 2 and possibly Scope 3 requirements, along with significant tailpipe emission requirements and other rules that are going to come to the US in 2023. One can imagine that if I don't have my rules in alignment, I could, as an innocent EV owner, purchase a vehicle that was manufactured using inappropriate labor sources with materials that were mined in non-environmentally friendly ways and powered by non-environmentally friendly coal fired electrical plants. [00:17:39.120] - Bill Newman So just because you drive an EV doesn't mean that you're being ecologically mindful. You have to really understand where it's all coming from and how you're using it. So sustainability plays a huge role there. We're going to see more regulatory impacts and reporting impacts as we go into 2023. And frankly, that works for people who want to drive gas powered vehicles as well. They're complex pieces of machinery and whether you have an affinity to drive gas powered electric or what have you, there's no guarantee that just because you climb behind a wheel, some gas powered vehicles are actually more sustainable than EVs. So it's not a black and white thing. Just to use the expression, you really have to go under the hood to understand what's going on there so that you're putting your money in a meaningful way in a place where you can act accordingly based on your beliefs for what sustainability means for you. [00:18:48.360] - Mustansir Saifuddin I think you just hit it really right on the point when you talk about you really have to look under the hood to see what's going on. That's a good advice for our listeners to keep that in mind when you look at sustainability and how big of a role it plays overall. I think that brings us to the end of our conversation. Like I say always, what is the one take away from this particular topic that you're talking about that you want our listeners to keep in mind how we move through 2023? [00:19:26.100] - Bill Newman Well, I think on the topic of EVs, just to wrap up the last piece that we were discussing, I think you have to decide what kind of an impact and how early you want to make, if you are going to be a green buyer and be conscientious and put your money where your mouth is. And for those people who really want to make an impact right now, immediately, and feel good about what they're doing over the next 5 to 10 years with the environment, buy a plug-in hybrid electric vehicle. It's proven technology. Do plug it in. Don't drive it like a gas powered vehicle because then you're no better off than if you're filling up at the gas station. But that's very finely tuned technology. It's multi generations old. If you do feel that compelled to go in and buy a full battery electric vehicle, also understand that the technology is going to significantly improve, not quite like Moore's Law, but you're going to see some significant improvements in vehicle performance and comfort. Maybe not reliability because they're generally very high quality vehicles built today. But certainly in terms of battery capacity range, etc. You're going to see some real significant improvements in the next two to three years. [00:20:51.240] - Bill Newman But again, plan to drive the car for 10 years, 15 years, 20 years. That's how they're built. And that's a real change in the mindset, particularly of North American auto consumers who, as recent as 20 years ago, generally bought or leased a new car every 4 to 6 years. We're moving away from that. So be really happy and confident in the purchase, particularly that you're making when and if you do go in for a form of electric vehicle. And that way you'll be quite satisfied over the period of ownership. [00:21:33.120] - Mustansir Saifuddin That's a good advice to keep in mind. Thank you so much, Bill. It has been a pleasure talking with you. And it was a great conversation, especially this topic has been lingering and a lot of folks have questions in terms of how we are seeing the market now, but also what is the future holds for them. So thank you again for sharing your insights into this topic. [00:21:58.240] - Bill Newman Great to be with you again. Take care. Have a great day. [00:22:02.340] - Mustansir Saifuddin You too. Thank you. [00:22:07.920] - Mustansir Saifuddin Thanks for listening to Tech Driven Business brought to you by Innovative Solution Partners. Bill covered so many aspects of the quickly evolving EV market. His main take away? Decide what environmental impact you want to make and when. We would love to hear from you. Continue the conversation by connecting with me on LinkedIn or Twitter. Learn more about Innovation Solution Partners and schedule a free consultation by visiting isolutionpartners.com. Never miss a podcast by subscribing to our YouTube channel. Information is in the show notes.

Bill Newman FULL DL 20230127 - 0906

Play Episode Listen Later Jan 27, 2023 49:46

Bill Newman FULL DL 20230127 - 0906 by WHMP Radio

bill newman

Bill Newman FULL DL 20230126 - 0906

Play Episode Listen Later Jan 26, 2023 53:59

Bill Newman FULL DL 20230126 - 0906 by WHMP Radio

bill newman

Inside Insights: Workforce Planning for 2023 & Beyond with William ”Bill” Newman

Play Episode Listen Later Jan 24, 2023 20:27

In this next series of Tech-Driven Business, William ("Bill") Newman, Industry Executive Advisor at SAP North America, rejoins Mustansir Saifuddin to discuss how Workforce Planning has evolved through out the pandemic. This includes Diversity, Equity, and Inclusion (DEI) initiatives, changes in business operational styles, talent acquisition and retention, and how SAP is playing a role in this landscape. From not only supporting customers with their talent attraction and retention to providing access to education to expand the talent pool, SAP continues to be an important player in the tech industry. Bill has over 35 years of executive leadership, strategy, consulting, practice management experience balanced with extensive public speaking and higher education experience. A former leadership team member for Volkswagen's IT division, he is the author of two books on enterprise performance and has worked with many OEMs and suppliers across the automotive industry. Connect with Us: LinkedIn: Bill Newman Mustansir Saifuddin Innovative Solution Partners Twitter: @william_newman @Mmsaifuddin Instagram @billwine5 YouTube @isolutionpartners or learn more about our sponsor Innovative Solution Partners to schedule a free consultation. Episode Transcript [00:00:04.090] - Mustansir Saifuddin Welcome to Tech-driven Business. Brought to you by Innovative Solution Partners. In this first episode of a multipart series, I welcome back Bill Newman of SAP listen in as Bill shares his thoughts on how workforce planning has evolved in the pandemic. There are so many moving pieces to the puzzle and Bill hits on what businesses of all sizes should be aware of. [00:00:30.730] - Mustansir Saifuddin Hello, Bill. How are you? [00:00:33.530] - Bill Newman Great. Mustansir. Good to be back with you again. [00:00:36.970] - Mustansir Saifuddin Thank you. Thank you for joining us. It's been a while, so it's really good to have you back on our show. [00:00:42.590] - Bill Newman Good to be back with you. Good topic to revisit now that it's been a little while, for sure. [00:00:49.730] - Mustansir Saifuddin I think today we will focus on workforce planning and DEI. That's what we want to talk about and get some real examples from you and how things have progressed over since our last conversation. So if you're ready, we can get into our questions. [00:01:10.230] - Bill Newman Let's dive in. [00:01:12.390] - Mustansir Saifuddin Sounds good. So I know when you last joined me, we were in the midst of a pandemic, right? And looking back at 2022, what changes have you seen and where do you see us going? [00:01:28.330] - Bill Newman Well, I think the biggest change is that we're all we're all back together again, right? We're all working. We're working differently. So obviously there's a lot of technology that has been provided to enable remote work that's become mainstream. And in fact, in many cases, it's de facto. Whereas prior to the pandemic, we would say, tell me why we can't get together face to face. The kind of the thinking now is, tell me why we can't do this virtually. Right? Everybody's kind of enjoyed not only do they have the technology to work remotely, many people have enjoyed the fact that they haven't had to spend two, three, 4 hours a day commuting or traveling. So if we need to, we will. If we don't, why should we? It's even gotten to a point where a lot of our customers have asked their employees, tell me what days you would be willing to come into the office. And no big surprise, very few people lift their hand on Monday and Friday because they would like to spend those days at least working from home to have a little bit more of a work life or life work balance. [00:02:47.270] - Bill Newman But interestingly, everybody coming into the office on Wednesdays just creates the same traffic nightmare and parking anxiety that everybody had prior to the pandemic. So that's always an interesting facet. I think the way that we engage with people both in terms of how we bring them into the company and what our expectations are of them once they're in the company, I think has certainly changed. I think about some of the prioritizations and I guess what's a good word for it, some of the glamour that kind of went along with working for, say, for example, a high tech company in Silicon Valley. Well, guess what? You can probably work for that same company and work in Asheville, North Carolina, up in the mountains eating fish tacos at night. So there's really lots of different opportunities to work. So the glamour around working for some of these companies where you would come in, you get the ping pong table, you could bring your pet to work, you could get free lunches, free dinners, almost create an environment where you'd never want to leave, particularly if you were at the time of young millennial without a family. [00:04:13.570] - Bill Newman That pretext has gone away and that pretense doesn't make any sense anymore. We'll get into a couple of other things around workforce hiring and some of the things that are emerging around diversity and equality and inclusion or dei, which I think is very interesting as we do our look ahead. But those are some of the main and plain changes that we've seen since you and I were together, I think over a year ago. [00:04:44.490] - Mustansir Saifuddin Yeah, for sure. I think Bill and thanks for getting into like the nittygritty of what's going on and what we are seeing in this 2022 versus during the Pandemic. I think one of the things that was really stood out, especially for younger workforce, they find this as a new normal. And that has definitely put a lot of pressure on organizations to look at this as a going forward approach also right. In terms of how they should be operating, not just now coming out of the Pandemic, but in the long run, how should they be structured and what should be the criteria for the employees to be attracted to an organization or to associate with them. Right. In that fashion, I think it's safe. [00:05:35.780] - Bill Newman To say that geography has very little correlation to where we work and what we do anymore. And that is a huge game changer. [00:05:44.190] - Mustansir Saifuddin Yeah, for sure. That kind of takes me to looking ahead. So let's fast forward to 2023. What do you think organizations should be looking at and employees at the same time, right? What should be their focus as far as moving ahead in 2023? [00:06:07.190] - Bill Newman Well, I think on the topic of workforce planning, for sure, and I'll look at this through a manufacturing lens. So, you know, you and I are both manufacturing experts, so let's kind of stay in our base camp for the moment. There's going to be a significant amount of hiring that's still going to continue just because we decide to keep interest rates high. That's not going to take away the need from having people with both skilled trades as well as higher education, engineering especially, to come in and really contribute. So those talents will remain and will become very competitive across different kinds of manufacturing as well as non-manufacturing segments. So, again, remember, we took geography out of the equation. So you and I are today recording. We're both in Michigan. Tomorrow we could be looking at bringing somebody on board to our projects that could be in California, Arizona, Massachusetts, Florida and Georgia. Doesn't matter. We're all going to be enabled to come together. So I think that this idea of, again, where you work and where you live is now disassociated. And what that does is it creates a lot of competitiveness across industries and across industry sectors. [00:07:36.870] - Bill Newman So how we interview, I'm a big brand, you want to come and work for me? Maybe I'm not really interested in going through eight to ten interview cycles with you anymore. Maybe I can find a good job, a good next step in my career without having to make that kind of commitment that you expected to come work for a brand name company before the pandemic. So being able to get to figure out for employers, being able to figure out what's the talent we need, what does that skill mix look like, what's my preferred ratio of being in office or being remote? Does the position require being face to face? And if so, how much, how much virtualization can be needed, is needed to be successful? All of that you got to figure out ahead of time and then really compress the onboarding and hiring process. So that's for sure going to be a real challenge, particularly in this talent shortage and manufacturing, again, staying kind of our base camp. I think the other thing to look at and we'll lead into this topic around DEI, it's really in the mainstream now. So I'm going to refer to the recently published Original Equipment Supplier Association OESA study that was completed with Acadia just in December of 2022. [00:09:09.790] - Bill Newman It really spoke strongly and without going too deep into the report, just kind of give a couple of points. That over 60% of companies now in the automotive supplier space. So again, kind of stay in niche into one of our home bases here have active dei programs and of those, 60 plus percent are showing improvements or acceleration in those programs. And I'm really not just talking about making sure that you have a diverse workforce from a cultural or race or a gender perspective. It's actually also extending to socioeconomic background kind of in terms of culturally where your country of origin might be from, and also making sure that those DEI elements not only apply to new talent acquisition, but also to high potential programs to work shift opportunities. So if you did want to take a different shift in your skilled trade, maybe having that balance across for second and maybe even third shifts is important as well as in the boardroom. So you're not just going to see it at the front end and the back end of the career management process. You're going to see it all across the different elements of an employee journey, throughout the organization. [00:10:35.470] - Bill Newman And again, while manufacturing is going to be significantly short on effective and productive talent, you're going to see a real lean into that to keep those people happy, to keep them motivated and to keep them performing at very high levels with very high intrinsic value, for sure. [00:10:56.900] - Mustansir Saifuddin I think you mentioned about DEI and what role is being playing and how quickly it is getting integrated into the new normal. Right. That's amazing. With that being said, let's take a little detail over here on a personal note. I know you always have a pulse on what is going on in the industry. How are you able to do that? [00:11:23.370] - Bill Newman Well, I think it comes from a lot of years and knowing a lot of people and having done a lot of different things. I really do enjoy learning. I'm a naturally curious individual. I also enjoy meeting new people and hearing their perspective, particularly some of the lessons learned in the personal experiences coming out of the pandemic. I think we have a lot to offer each other and I think that just being able to be part of that conversation and maybe not contribute into the conversation as much as well as listening in and taking ideas away from the conversation, but certainly trying to frame a balance of that. And I think also, too, it's very interesting as the parent of Millennials now that the millennials are essentially running the workplace now. They're the largest generation in the workforce now by numbers. It's very interesting for me to see how the nature of business is changing now that essentially my kids generation are running business here, at least in North America. So I find that particularly interesting and in some cases highly entertaining. [00:12:47.650] - Mustansir Saifuddin I can totally relate to that. It's just different dynamics, right? That's for sure. [00:12:53.750] - Bill Newman Yeah, 100%. You know, things are things are very, very different and the different expectations that come with shaping those different generational life journeys is pretty interesting to watch. [00:13:08.010] - Mustansir Saifuddin Yeah. And I think that in a good way, it's happening and it's happening fairly, I would say at a very fast pace the way it's happening. But now looking back, like, let's do it from an organization's point of view, right. What's your take on how SAP is helping retool the workforce to make it easier for people to jump into it? What have you observed? [00:13:39.170] - Bill Newman Well, there are some things certainly that we can offer our customers that can make it a lot easier for them to manage their employee journey. So I think listeners are probably familiar with the fact that SAP has a special relationship with Qualtrics. Qualtrics does a lot of work around employee relationship and being able to kind of do those pulse surveys. And we did use those pulse surveys very significantly across a lot of industries during the pandemic. They were incredibly useful just to kind of keep a sense, particularly when we weren't together at all, to be able to keep a sense on where everybody was. The so called pulse check, I think also too that from a human experience management or human HR relationship type of perspective. We've always had tools to help with the onboarding and also the career management of employees. I just think that those are going to gain a higher level of importance, particularly as skilled trade and experienced talent particularly is harder to find and is harder to keep and as the demand grows. I think from a knowledge and community sharing, SAP has been very forward with online learning platforms such as Open SAP. [00:15:13.970] - Bill Newman So lots of education, a lot of content, a lot of knowledge available to go in and learn basically available for at free of charge in many cases. So just one zone time. And I think based on some of the experiences Mustansir that you and I have had within the user groups, is a very vibrant community within the user base, that allows for not only personal networking, but also for experiential learning as well as story sharing and other really great learning vehicles like that. So we're trying to do our best particularly inside of key industries and localized geographies where people may not be working but where they are resident. And I think that that will continue and become even more important in the coming years. [00:16:07.350] - Mustansir Saifuddin Yeah, I think you mentioned about SAP's role. I think I likely when throwing you mentioned about user groups and America's SAP User Group (ASUG) I will call them out on this and they have done a great job in kind of mixing in with the the new normal. How things are happening in 2022 after the Pandemic and having that virtual/in-person events, trying to meet up with the demands after the Pandemic, how things are moving forward and what are people looking at as far as learning and meeting up with each other, as well as collaboration. So I think we have a mixed bag of all the platforms that are currently available to the business community are coming along and moving into the direction that makes it much easier for organizations to manage how they are managing their workforce and especially this trend. Will we'll see how 2023 brings to the forefront in terms of what we have seen in 2022 and what is going to be a long term effect on how workforce planning goes in general right now, from an organizational point of view? So that being said, I know this was one thing that I always ask my guest what is that one takeaway that you want to share with our listeners and they should leave with that in this session? [00:17:58.970] - Bill Newman Well, kind of going back to trying to have a state of natural curiosity, I think listeners can always keep in mind or maybe take with them the fact that we can always learn something from one another. And you may have a highly pedigreed career over decades, but bringing a set of fresh eyes with a different perspective can be really kind of that spark moment that you need to either solve a critical business problem or really just find something intrinsic in your own personal growth journey. Doesn't matter what your age are or who you are, we all have that need, and I think being able to contribute and help shape each other and being open, I think that's really also another key. Being open to those messages when they come in will all make us much better people and make our businesses operate much more productively and efficiently, for sure. [00:19:09.570] - Mustansir Saifuddin Great advice. Thank you so much. This has been a great session with you, Bill, as always. Thank you and I look forward to talking with you in our next podcast. [00:19:21.810] - Bill Newman Sounds great. Look forward to it. Thanks for having me on. [00:19:27.750] - Mustansir Saifuddin Thanks for listening to Tech-Driven Business business brought to you by Innovative Solution Partners. Bill provided valuable insights on how workforce planning has changed over the last couple of years. His main takeaway? We can always learn from one another. Bringing a fresh set of ideas with a different perspective can be the spark movement you need to solve a business problem or for your own personal growth. We would love to hear from you. Continue the conversation by connecting with me on LinkedIn or Twitter. Learn more about Innovative Solution Partners and schedule a free consultation by visiting Isolutionpartners.com. Never miss a podcast by subscribing to our YouTube channel. Information is in the show notes.

Phil chats with Bill Newman (14/10)

WAY FM

Play Episode Listen Later Oct 13, 2022 9:55

Bill Newman has been travelling Australia, and the world, speaking about the love of Jesus. He is in Tasmania now and will be at Gateway Baptist Church this Sunday from 7 (along with some great music). This event is not to be missed!

jesus christ australia interview tasmania bill newman gateway baptist church

Renewing A Passion for the Gospel - Bill Newman (Evangelist) - 11 Oct 2022

australia passion gospel evangelist renewing bill newman

Play Episode Listen Later Oct 11, 2022 41:52

We’re talking to Australia’s best known and most loved Evangelist Bill Newman. Help Vision to keep 'Connecting Faith to Life': https://vision.org.au/donateSee omnystudio.com/listener for privacy information.

The Future of Wine Culture, Wine Tourism & Technology: L'Chaim!

Play Episode Listen Later Apr 20, 2022 60:00

The Buzz 1: Wine tourism —aka oenotourism, enotourism, vinitourism— lures wine lovers to vineyards, wineries, cellars, and museums dedicated to wine. The wine tourism global market size is expected to more than triple by 2030 to ~29.6B euros. (statista.com) The Buzz 2: According to a late-2020 www.statista.com survey, wine tourists are mainly casual wine tasters rather than wine geeks. The Buzz 3: People in Portugal consume more wine than any other country worldwide, with an annual per capita consumption of 52 liters in 2020. Next is Italy: 47 liters per capita. The Buzz 4: Decanter Magazine publishes wine travel guides to ?Italy, ?South Africa, ?Europe and the UK. Wwinepaths.com/ organizes luxury wine tours, intimate group trips and wine holidays around the world. Winemag.com reports on wine travel from touring the historic underground caves of Champagne to playing winemaker for a day in California's Napa Valley. We'll ask Bill Newman, Beth Kaczmarek, Christian Oggenfuss, and Brenda Boudreaux for their take on The Future of Wine Culture, Wine Tourism and Technology: L'Chaim!

The Future of Wine Culture, Wine Tourism & Technology: L'Chaim!

Play Episode Listen Later Apr 20, 2022 55:09

The Buzz 1: Wine tourism —aka oenotourism, enotourism, vinitourism— lures wine lovers to vineyards, wineries, cellars, and museums dedicated to wine. The wine tourism global market size is expected to more than triple by 2030 to ~29.6B euros. (statista.com) The Buzz 2: According to a late-2020 www.statista.com survey, wine tourists are mainly casual wine tasters rather than wine geeks. The Buzz 3: People in Portugal consume more wine than any other country worldwide, with an annual per capita consumption of 52 liters in 2020. Next is Italy: 47 liters per capita. The Buzz 4: Decanter Magazine publishes wine travel guides to ?Italy, ?South Africa, ?Europe and the UK. Wwinepaths.com/ organizes luxury wine tours, intimate group trips and wine holidays around the world. Winemag.com reports on wine travel from touring the historic underground caves of Champagne to playing winemaker for a day in California's Napa Valley. We'll ask Bill Newman, Beth Kaczmarek, Christian Oggenfuss, and Brenda Boudreaux for their take on The Future of Wine Culture, Wine Tourism and Technology: L'Chaim!

The Future of Wine Culture, Wine Tourism & Technology: L'Chaim!

Play Episode Listen Later Apr 20, 2022 55:09

The Buzz 1: Wine tourism —aka oenotourism, enotourism, vinitourism— lures wine lovers to vineyards, wineries, cellars, and museums dedicated to wine. The wine tourism global market size is expected to more than triple by 2030 to ~29.6B euros. (statista.com) The Buzz 2: According to a late-2020 www.statista.com survey, wine tourists are mainly casual wine tasters rather than wine geeks. The Buzz 3: People in Portugal consume more wine than any other country worldwide, with an annual per capita consumption of 52 liters in 2020. Next is Italy: 47 liters per capita. The Buzz 4: Decanter Magazine publishes wine travel guides to ?Italy, ?South Africa, ?Europe and the UK. Wwinepaths.com/ organizes luxury wine tours, intimate group trips and wine holidays around the world. Winemag.com reports on wine travel from touring the historic underground caves of Champagne to playing winemaker for a day in California's Napa Valley. We'll ask Bill Newman, Beth Kaczmarek, Christian Oggenfuss, and Brenda Boudreaux for their take on The Future of Wine Culture, Wine Tourism and Technology: L'Chaim!

1196: Royal College of Ophthalmologists: Interview with Ophthalmologist Bill Newman

RNIB Conversations

Play Episode Listen Later Apr 7, 2022 16:25

All Ophthalmologist's or Eye Doctors in the UK are overseen by the Royal College of Ophthalmologists, the only professional membership body for medically qualified ophthalmologists and those who are training to become one too. The Royal College of Ophthalmologists champions excellence in the practice of ophthalmology for the benefit of patients and the public, supporting the improvements of eye care within the health care system. The College was originally formed from the Ophthalmological Society of the United Kingdom and the Faculty of Ophthalmologists. The College received it's Royal Charter on 1 April 1988 and granted with a Royal Licence 5 years later. RNIB Connect Radio's Toby Davey caught up with Ophthalmologist Bill Newman who is currently the Head of the Professional Standards Committee at the college to find out what Professional Standards within the college is all about, along with some of the legal work Bill is involved in around driving licences and his role as Medical Director of a large eye Hospital in the North West. To find out more about The Royal College of Ophthalmologists, information around Ophthalmology and the work the college does to champion high quality eye care for patients do visit the College's website - https://www.rcophth.ac.uk (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath)

head uk college united kingdom hospitals faculty northwest medical director royal college ophthalmology ophthalmologists eye doctors professional standards rnib royal charter professional standards committee bill newman rnib connect radio

'Some Enchanted Evening' - Actor, Showman and Theatre Restaurant Impresario; John Newman

STAGES with Peter Eyers

Play Episode Listen Later Mar 30, 2022 88:00

John Newman is the savvy entrepreneur who pioneered the glory of theatre restaurant in Australia, with the establishment of the iconic Tikki & John's in Melbourne. The venue fast became an institution in the city and a haven for a stellar cast of performers. With wife Tikki Taylor, he founded an entertainment dynasty spawning further theatre dining experiences such as Dracula's, Cafe Crypt and Crazyhouse.John Newman is a Geelong boy whose parents were publicans. He was born to perform and garnered early experiences entertaining hotel guests. He joined the Geelong Musical Comedy Company, a flourishing amateur group whose members also included John's brother Bill, Ernie Bourne and Barry Crocker. His success in comic and singing roles with that company, prompted him to embark on show business as a profession.He joined an outfit calling itself, rather ambitiously The South Pacific Film and Television Company, which planned to hit the high spots with a grand tour of Victorian country areas. The variety show, in which John did comedy, magic and his impressions of Groucho Marx and other stars of the day, played Geelong, Colac and Camperdown. He was next a member of the Blind Institute Concert Party, which performed everywhere in Victoria in one - and - two night stands, raising money for the institute. John stayed with the unit for two years, and then he left to go into the chorus of the J. C. Williamson Song of Norway.The run of Song of Norway was followed by a revival of Annie Get Your Gun, with Evie Hayes and Hayes Gordon, and John then went into the chorus of South Pacific, where he met Joyce Taylor (Tikki),Tikki Taylor had studied dancing at the Jenny Brennan Academy and appeared on stage for the first time in a juvenile role in Blue Mountain Melody, an Australian musical which starred Cyril Ritchard and Madge Elliott. After pursuing a classical ballet career she joined J.C. Williamsons as a show dancer, her first show being The Desert Song with Max Oldaker. Then followed Rose Marie, White Horse Inn, No, No, Nanette, The Girl Friend, Follow The Girls and Oklahoma, in which she understudied three roles, eventually playing the lead comedienne, Ado Annie.John and Tikki combined both their professional and private lives working in the same shows. They formed an act and toured it through the U.K. for eighteen months with top Australian magician The Great Levant covering England, Scotland and Wales. After that, they toured the U.S. Army bases in Europe.Back in London they saw the latest American musical hit The Pajama Game, and John knew that Tikki would be perfect for the comedy-dancing role of Gladys Hotchkiss. They rushed back to Australia and with the support of choreographer Betty Pounder and stage director Ian Roberts, Tikki managed to persuade the JCW management that it was not necessary to import an American actress for the role. This seminal production embraced an all-Australian company including Toni Lamond, Jill Perryman and John's brother Bill Newman.John worked in the chorus of The Pajama Game and joined Tikki in subsequent productions of Can-Can, For Amusement Only and Grab Me A Gondola. Tikki and John raised a family, pursued television appearances and then Tikki made a comeback to the stage as Minnie Fay in Hello Dolly.Television claimed John for a while guided by the famous American entrepreneur Larry K. Nixon; then a stint as Victorian manager for NLT Productions, and producer of The Ray Taylor Show on ATV0 in its early days. John was later Company manager for the Moscow Circus before he and Tikki made their decision to go into the restaurant business.Tikki Taylor and John Newman had show business in their blood. Both were already entertaining as children. When they met and married, they changed the course of theatre history in Melbourne. It is indeed an entertaining life!The STAGES podcast is available to access and subscribe from Whooshkaa, Spotify and Apple podcasts. Or from wherever you access your favourite podcasts. A conversation with creatives about craft and career. Recipient of Best New Podcast at 2019 Australian Podcast Awards. Follow socials on instagram (stagespodcast) and facebook (Stages).www.stagespodcast.com.au

american spotify australia europe apple england song australian army theater scotland oklahoma restaurants actor melbourne television norway wales stages dracula victorian recipients south pacific enchanted musical theatre geelong showman groucho marx hello dolly john newman rose marie australian podcast awards can can annie get your gun ian roberts impresario jcw pajama game best new podcast whooshkaa white horse inn desert song tikki colac camperdown double act ado annie bill newman williamsons barry crocker minnie fay for amusement only

The Proclaimer - 40 Years of Inspiring Stories - Bill Newman (Evangelist) - 24 Jan 2022

gospel evangelist inspiring stories bill newman

Play Episode Listen Later Jan 24, 2022 50:37

We're talking to Evangelist Bill Newman about the release of his latest book reflecting on 40 years proclaiming the Gospel around the world. Help Vision to keep 'Connecting Faith to Life': https://vision.org.au/donate See omnystudio.com/listener for privacy information.

The "Great ReBuild" with Brian Irwin and Bill Newman

Play Episode Listen Later Nov 30, 2021 60:00

Automotive Insiders is presented by OESA, the Original Equipment Suppliers Association. Industry experts discuss Automotive hot topics to keep the Automotive Supplier Community up to date on the fast-changing mobility landscape. From post-pandemic manufacturing restart planning and worker safety measures, to legal issues and supply chain disruptions, Automotive Insiders is your source of timely and relevant content. Host Bonnie D. Graham welcomes Brian Irwin, Managing Director and lead of Accenture's Automotive and Mobility practice across North America, and Bill Newman, North America Executive Industry Advisor / Chief at SAP. Brian Irwin and Bill Newman discuss how supply chain challenges today truly feel like a “perfect storm”. Brian observes, “Automotive suppliers need to understand how we got here today and how we can prevent this from happening again. Supply chain is truly the heart of today's Automotive organization and they need to rebuild the heart of the company. Automotive organizations can use their supply chain to rethink their business model and to gain competitive advantage. Be sure to listen to the full conversation for more of their expert insights. For information about upcoming OESA events, visit OESA.org. Industry insights on previous OESA podcasts: Automotive Insiders.

business technology news north america resilience managing directors supply supply chains rebuild mobility sap accenture automotive suppliers voiceamerica mema bill newman bonnie d. graham brian irwin oesa bonnie d graham

Disrupting Supply Chain Disruption with SAP and Accenture

bubbles dan thompson oil painting bill newman

Play Episode Listen Later Nov 16, 2021 60:00

Automotive Insiders is presented by OESA, the Original Equipment Suppliers Association. Industry experts discuss Automotive hot topics to keep the Automotive Supplier Community up to date on the fast-changing mobility landscape. From post-pandemic manufacturing restart planning and worker safety measures, to legal issues and supply chain disruptions, Automotive Insiders is your source of timely and relevant content. Host Bonnie D. Graham welcomes Bill Newman, North America Executive Industry Advisor / Chief at SAP and Brian Irwin, Managing Director and lead of Accenture's Automotive and Mobility practice across North America. Bill Newman and Brian Irwin discuss how supply disruptions have increased the need for demand sensing and planning throughout the value chain. Bill observes, “Digital methods are creating unique ‘win' moments over companies still using traditional approaches. Supplier management and collaboration are paramount. It is critical to understand how your suppliers support your products going into available vehicles.” Balancing complex operations – and material flow inside plant operations – to maximize available output and revenue will enable large suppliers and vehicle makers to maximize revenue and profit per vehicle program. Be sure to hear the full conversation with more of their expert insights. For information about upcoming OESA events, visit OESA.org. Industry insights on previous OESA podcasts: Automotive Insiders.

business technology news digital north america balancing managing directors disruption supply chains mobility disrupting sap accenture automotive supplier suppliers voiceamerica supply chain disruption mema bill newman bonnie d. graham brian irwin oesa bonnie d graham

"Art Bubbles" Sub Episodes, #2 With Dan Thompson

The House Of Oaxaca

Play Episode Listen Later Nov 11, 2021 103:19

Art Bubble Hosts Teresa Oaxaca and Suzanne Lago Arthur interview artist Dan Thompson about his early years in the art world, his enduring fascination with seeing and investigating multiple dimensions into the human figure and portraiture, and important links in recent art history of the last century. The House Of Oaxaca Podcast- https://www.houseofoaxaca.com/podcastTeresa Oaxaca- https://www.teresaoaxaca.com/Suzanne Lago Arthur- https://www.lagoarthurstudio.com/Dan Thompson- https://www.danthompsonart.com

95. Hello Newman

The Hudson Valley Disc Golf Podcast

Play Episode Listen Later Oct 15, 2021 57:27

Jack has a chat with Bill Newman about a Throw Pink event this Saturday, October 16th at FDR State Park in Yorktown. Jack then (but before) talks with Ryan, Jasan and Jaimen who, though he won The Hunt for Joralemon's Lost Treasure, you wouldn't know it if you listen to this episode. They play some Pirate Trivia, talk some Joralemon's Treasure but we barely even mention Jaimen's win.

hunt newman yorktown lost treasures bill newman jasan

Operational Resilience Insights: Martin Bilderbeck & Bill Newman

Play Episode Listen Later Oct 5, 2021 60:00

Automotive Insiders is presented by OESA, the Original Equipment Suppliers Association. Industry experts discuss Automotive hot topics to keep the Automotive Supplier Community up to date on the fast-changing mobility landscape. From post-pandemic manufacturing restart planning and worker safety measures, to legal issues and supply chain disruptions, Automotive Insiders is your source of timely and relevant content. Host Bonnie D. Graham welcomes Martin Bilderbeck, Director of Business Development in the Automotive Sector at Capgemini North America, and Bill Newman, North America Executive Industry Advisor / Chief at SAP. Today, 18 months into the global pandemic, what is changing and what is remaining the same as automotive companies look to improve operational resilience? As automotive suppliers worked through the COVID-19 recession, key processes and operating models once believed to be elective had become essential to create go-forward business resilience. Martin and Bill explore the evolution to electric vehicles, ongoing supply chain stressors and disruptions, and harnessing the power of data to become an intelligent industry. For information about upcoming OESA events, visit OESA.org. To hear industry insights on previous OESA podcasts: Automotive Insiders.

covid-19 director business technology news data resilience operations business development supply chains sap automotive electric vehicles operational suppliers capgemini voiceamerica mema operational resilience bill newman bonnie d. graham oesa bonnie d graham

Inside Insights: Future of Work with Bill Newman

Play Episode Listen Later Sep 27, 2021 19:47

We continue the conversation with William ("Bill") Newman, Industry Executive Advisor (Chief), Automotive for the Customer Innovation Office at SAP North America, about the Future of Work, especially within the Automotive Industry. Bill covers topics like hybrid work models, the role of technology in the future of work, setting expectations, and highlights how SAP is supporting its customers and employees. Bill has over 35 years of executive leadership, strategy, consulting, practice management experience balanced with extensive public speaking and higher education experience. A former leadership team member for Volkswagen's IT division, he is the author of two books on enterprise performance and has worked with many OEMs and suppliers across the automotive industry. Continue the conversation on: LinkedIn: Bill Newman, Mustansir Saifuddin, Innovative Solution Partners Twitter: @Mmsaifuddin YouTube or learn more about our sponsor Innovative Solution Partners and schedule a free consultation.

future of work volkswagen sap automotive oems automotive industry bill newman sap north america

Inside Insights: Next Generation Workforce with Bill Newman

Play Episode Listen Later Sep 13, 2021 17:51

In this next set of episodes, we switch gears and focus on the people component. William ("Bill") Newman, Industry Executive Advisor (Chief), Automotive for the Customer Innovation Office at SAP North America, discusses workforce issues that many businesses currently face: an aging workforce, a changing workforce, and how to survive when technology keeps changing and your workforce may not be ready. Bill has over 35 years of executive leadership, strategy, consulting, practice management experience balanced with extensive public speaking and higher education experience. A former leadership team member for Volkswagen's IT division, he is the author of two books on enterprise performance and has worked with many OEMs and suppliers across the automotive industry. Continue the conversation on: LinkedIn: Bill Newman, Mustansir Saifuddin, Innovative Solution Partners Twitter: @Mmsaifuddin YouTube or learn more about our sponsor Innovative Solution Partners to schedule a free consultation.

next generation workforce volkswagen automotive oems bill newman sap north america

The Future of Wineries and Technology: The Move to Crowd-Sourced

Play Episode Listen Later Jul 7, 2021 55:49

The Buzz 1: “Virtual vintners have a say on grape varieties, barrels and bottling. Crowd-sourcing has become the Internet's new favorite method of financing start-ups, authors and researchers. Now two wineries have adopted the idea to get their consumers involved in making wine.” (www.washingtonpost.com/lifestyle/food/crowd-sourced-wine-virtual-vintners-have-a-say-on-grape-varieties-barrels-and-bottling/2014/08/29/aac1bd8c-2e26-11e4-994d-202962a9150c_story.html) The Buzz 2: “Our Cabernet Sauvignon has been picked and crushed, and the yeast strain and fermentation tannins YOU selected have been added.…They did not pick the yeast that I normally use,” winemaker Tom Johnson says. Silversmith's 797 Facebook fans voted on winemaking decisions for the 2011 vintage. “I thought no one would be interested and no one would participate. Boy was I wrong.” (winefashionista.com/2011/11/04/turning-winemaking-over-to-facebook-fans) We'll ask Bill Newman, Alexander Wong, Neil Collins, and Jim Bernau, for their take on The Future of Wineries and Technology: The Move to Crowd-Sourced and Crowd-Crushed.

business internet technology future virtual wine boy crowd buzz wineries crowdsourcing sourced voiceamerica tom johnson silversmith internet talk radio bill newman neil collins bonnie graham voiceamerica business alexander wong

The Future of Wineries and Technology: The Move to Crowd-Sourced

Play Episode Listen Later Jul 7, 2021 55:49

The Buzz 1: “Virtual vintners have a say on grape varieties, barrels and bottling. Crowd-sourcing has become the Internet's new favorite method of financing start-ups, authors and researchers. Now two wineries have adopted the idea to get their consumers involved in making wine.” (www.washingtonpost.com/lifestyle/food/crowd-sourced-wine-virtual-vintners-have-a-say-on-grape-varieties-barrels-and-bottling/2014/08/29/aac1bd8c-2e26-11e4-994d-202962a9150c_story.html) The Buzz 2: “Our Cabernet Sauvignon has been picked and crushed, and the yeast strain and fermentation tannins YOU selected have been added.…They did not pick the yeast that I normally use,” winemaker Tom Johnson says. Silversmith's 797 Facebook fans voted on winemaking decisions for the 2011 vintage. “I thought no one would be interested and no one would participate. Boy was I wrong.” (winefashionista.com/2011/11/04/turning-winemaking-over-to-facebook-fans) We'll ask Bill Newman, Alexander Wong, Neil Collins, and Jim Bernau, for their take on The Future of Wineries and Technology: The Move to Crowd-Sourced and Crowd-Crushed.

business internet technology future virtual wine boy crowd buzz wineries crowdsourcing sourced voiceamerica tom johnson silversmith internet talk radio bill newman neil collins bonnie graham voiceamerica business alexander wong

The Future of Wineries and Technology: The Move to Crowd-Sourced

Play Episode Listen Later Jul 7, 2021 55:49

The Buzz 1: “Virtual vintners have a say on grape varieties, barrels and bottling. Crowd-sourcing has become the Internet's new favorite method of financing start-ups, authors and researchers. Now two wineries have adopted the idea to get their consumers involved in making wine.” (www.washingtonpost.com/lifestyle/food/crowd-sourced-wine-virtual-vintners-have-a-say-on-grape-varieties-barrels-and-bottling/2014/08/29/aac1bd8c-2e26-11e4-994d-202962a9150c_story.html) The Buzz 2: “Our Cabernet Sauvignon has been picked and crushed, and the yeast strain and fermentation tannins YOU selected have been added.…They did not pick the yeast that I normally use,” winemaker Tom Johnson says. Silversmith's 797 Facebook fans voted on winemaking decisions for the 2011 vintage. “I thought no one would be interested and no one would participate. Boy was I wrong.” (winefashionista.com/2011/11/04/turning-winemaking-over-to-facebook-fans) We'll ask Bill Newman, Alexander Wong, Neil Collins, and Jim Bernau, for their take on The Future of Wineries and Technology: The Move to Crowd-Sourced and Crowd-Crushed.

business internet technology future virtual wine boy crowd buzz wineries crowdsourcing sourced voiceamerica tom johnson silversmith internet talk radio bill newman neil collins bonnie graham voiceamerica business alexander wong

When Good Car Companies Create Great Profits & Know What They Are

Play Episode Listen Later Apr 28, 2021 60:00

Automotive Insiders is presented by OESA, the Original Equipment Suppliers Association. Industry experts discuss Automotive hot topics to keep the Automotive Supplier Community up to date on the fast-changing mobility landscape. From post-pandemic manufacturing restart planning and worker safety measures, to legal issues and supply chain disruptions, Automotive Insiders is your source of timely and relevant content. Host Bonnie D. Graham welcomes Deloitte's Kevin Foster and SAP's Bill Newman for a round table discussion on “When Good Car Companies Create Great Profits…and Know What They Are.” The conversation covers automotive disruptors and impacts on the current automotive landscape; the capabilities required to operate in the ‘new world'; how increased visibility to cost-drivers can help businesses accelerate profitability; and how a common data model and integration of business processes can help increase cost savings, sales and profitability. Don't miss this insight-packed episode. More info: OESA.org

covid-19 business technology news companies supply profits manufacturing mobility deloitte sap automotive oem suppliers voiceamerica kevin foster bill newman bonnie d. graham oesa bonnie d graham

People, Vehicles and Profit with Bill Newman and Kevin Foster

Play Episode Listen Later Apr 26, 2021 60:00

Automotive Insiders is presented by OESA, the Original Equipment Suppliers Association. Industry experts discuss Automotive hot topics to keep the Automotive Supplier Community up to date on the fast-changing mobility landscape. From post-pandemic manufacturing restart planning and worker safety measures, to legal issues and supply chain disruptions, Automotive Insiders is your source of timely and relevant content. Host Bonnie D. Graham welcomes SAP's Bill Newman and Deloitte's Kevin Foster for a People, Vehicles and Profit round table discussion on timely topics important to vehicle makers, distributors and complex supplier assemblies. The podcast title is a paraphrase of the late Lee Iacoca's well-known quote, “In the end, all business operations can be reduced to three words: people, product, and profit.” The conversation covers vehicle logistics and profitability; the value of understanding vehicle demand; the need for accuracy in cost build-up and activity-based costing models; and the importance of aggregating sales revenue data to achieve a clear profit vision. Don't miss this insight-packed episode! More info: OESA.org

covid-19 business technology news profit vehicles mobility deloitte sap automotive electric vehicles oem suppliers voiceamerica kevin foster bill newman bonnie d. graham oesa bonnie d graham

Bill Newman Returns: Post-Pandemic Automotive Resilience and More

Play Episode Listen Later Apr 5, 2021 60:00

Automotive Insiders is presented by OESA, the Original Equipment Suppliers Association. Industry experts discuss Automotive hot topics to keep the Automotive Supplier Community up to date on the fast-changing mobility landscape. From post-pandemic manufacturing restart planning and worker safety measures, to legal issues and supply chain disruptions, Automotive Insiders is your source of timely and relevant content. Host Bonnie D. Graham welcomes back SAP's Bill Newman to share his expertise on a range of timely automotive industry topics. Bill covers what the new Automotive Resilience look like a year after the start of the pandemic, including 2019 inadequacies, Covid-19 shutdown impacts, and pandemic liquidity effects in the supply base. He explains why supply chain “wobbles” have abated yet shortages still exist, including steady state of demand side supply planning, key shortages of components like semiconductor chips and batteries, and new policies around industrialization of regional supply capacity in North America. Bill also discusses changes in what and how the industry will build, including the BEV electrification uptick, and the importance of business succession planning for suppliers. More info: OESA.org Don't miss this insight-packed episode.

covid-19 business technology news north america resilience mobility post pandemic sap automotive electric vehicles oem suppliers voiceamerica bill newman bonnie d. graham oesa bonnie d graham

Fasten Your Seatbelt: Ready for Your Future Ride? Part 2

Play Episode Listen Later Mar 18, 2020 55:20

Today's buzz: “Auto makers look into their crystal balls – and their shops – to get an idea as to what's fueling the car of 2025. Most car makers agree: The next 10 years will see more change in the auto business than the last 20” (theglobeandmail.com). “Self-driving cars…once found only in science fiction, are about to become a reality” (Goldman Sachs, 2016). “When you think of a flying car one might think of The Jetsons. The company Terrafugia is working to get its flying car off the ground by 2025” (Business Insider, 2016). “In any major city in the world, you'll find smog…mostly from cars, SUVs, and pickup trucks…things are about to get better.…the car won't disappear, it will just be powered by different energies, and in some cases, take on new shapes” (thoughtco.com). We'll ask the experts for their take: Meg Divitto, Divitto Design Group; Mike Lackey, SAP; Marty Groover, C5MI; and Bill Newman, SAP. Join us for Fasten Your Seatbelt: Ready for Your Future Ride? – Part 2.

business technology ride auto cars goldman sachs business insider sap automotive fasten suvs jetsons seatbelts voiceamerica auton internet talk radio bill newman bonnie graham terrafugia mike lackey

Fasten Your Seatbelt: Ready for Your Future Ride? Part 2

Play Episode Listen Later Mar 18, 2020 55:20

Today's buzz: “Auto makers look into their crystal balls – and their shops – to get an idea as to what's fueling the car of 2025. Most car makers agree: The next 10 years will see more change in the auto business than the last 20” (theglobeandmail.com). “Self-driving cars…once found only in science fiction, are about to become a reality” (Goldman Sachs, 2016). “When you think of a flying car one might think of The Jetsons. The company Terrafugia is working to get its flying car off the ground by 2025” (Business Insider, 2016). “In any major city in the world, you'll find smog…mostly from cars, SUVs, and pickup trucks…things are about to get better.…the car won't disappear, it will just be powered by different energies, and in some cases, take on new shapes” (thoughtco.com). We'll ask the experts for their take: Meg Divitto, Divitto Design Group; Mike Lackey, SAP; Marty Groover, C5MI; and Bill Newman, SAP. Join us for Fasten Your Seatbelt: Ready for Your Future Ride? – Part 2.

business technology ride auto cars goldman sachs business insider sap automotive fasten suvs jetsons seatbelts voiceamerica auton internet talk radio bill newman bonnie graham terrafugia mike lackey

Game-Changers Crystal Ball 2018 Predictions - Part 3

Play Episode Listen Later Jan 3, 2018 54:54

The buzz: Welcome to 2018! If your #1 business wish is to know what 2018 holds for your company, industry and the world, we've got the next best thing. We're bringing you predictions from 70 thought leaders on the technologies, strategies, and trends that can help you grow and compete in 2018 and beyond. Pour a cup of Joe, Earl, or Dom, and join us for SAP Game-Changers Radio 2018 Predictions–Part 3 live. And mark your calendar for Jan. 10 [Part 4] and Jan. 17 [Part 5]. All episodes will be on-demand. You'll hear from Brynne Tillman, Vengreso; Rasmus Nelund, NNIT; Thiagu Bala, Deloitte; Rob Kugel, Ventana Research; Owen Pettiford, BackOffice Associates; Bryan Mattimore, Growth Engine Company; Seth Marlow, Wells Fargo; Susanne Seitinger, Philips Lighting; Annie Hayward, SAP; Ronald Schell, Metropolitan Utilities District; Bill Newman, SAP; Mike Lackey, SAP; Ben Zimmerman, EY; Patrick Hickey, Jump Analytics; Peter Ebert, Cryptowerk Corp. Happy New Year from SAP Game-Changers Radio!

business technology future happy new year predictions game changers dom earl deloitte sap wells fargo thought leaders ey futurist crystal balls voiceamerica 2018 predictions brynne tillman vengreso internet talk radio philips lighting game changers radio nnit patrick hickey bryan mattimore bill newman bonnie graham mike lackey growth engine company sap game-changers radio

Game-Changers Crystal Ball 2018 Predictions - Part 3

Play Episode Listen Later Jan 3, 2018 54:54

The buzz: Welcome to 2018! If your #1 business wish is to know what 2018 holds for your company, industry and the world, we've got the next best thing. We're bringing you predictions from 70 thought leaders on the technologies, strategies, and trends that can help you grow and compete in 2018 and beyond. Pour a cup of Joe, Earl, or Dom, and join us for SAP Game-Changers Radio 2018 Predictions–Part 3 live. And mark your calendar for Jan. 10 [Part 4] and Jan. 17 [Part 5]. All episodes will be on-demand. You'll hear from Brynne Tillman, Vengreso; Rasmus Nelund, NNIT; Thiagu Bala, Deloitte; Rob Kugel, Ventana Research; Owen Pettiford, BackOffice Associates; Bryan Mattimore, Growth Engine Company; Seth Marlow, Wells Fargo; Susanne Seitinger, Philips Lighting; Annie Hayward, SAP; Ronald Schell, Metropolitan Utilities District; Bill Newman, SAP; Mike Lackey, SAP; Ben Zimmerman, EY; Patrick Hickey, Jump Analytics; Peter Ebert, Cryptowerk Corp. Happy New Year from SAP Game-Changers Radio!

business technology future happy new year predictions game changers dom earl deloitte sap wells fargo thought leaders ey futurist crystal balls voiceamerica 2018 predictions brynne tillman vengreso internet talk radio philips lighting game changers radio nnit patrick hickey bryan mattimore bill newman bonnie graham mike lackey growth engine company sap game-changers radio

Jack Duffy JFK assassination 2013 10 24

The Opperman Report

Play Episode Listen Later Jun 2, 2014 117:43

Jack Duffy, author of "The Man From 2063", is an expert on the assassination of President Kennedy. He became interested in the JFK assassination after seeing a bootleg copy of the famous Zapruder film of President Kennedy's fatal motorcade in 1972. He has been researching the assassination ever since. Jack's entertaining book draws on his deep knowledge and personal research into the President's murder and is therefore based on actual events and people surrounding the assassination. Jack has interviewed many key eyewitnesses to the assassination of President John Kennedy, including Buell Frazier, Jean Hill, Mary Moorman, Beverly Oliver, and Bill Newman. He has also interviewed 2 surgeons who treated JFK at Parkland hospital - Dr. Robert McClelland and Dr. Charles Crenshaw. He has interviewed Marina Oswald. Jack has also met many researchers who have written books on the assassination including Vincent Bugliosi, Mark Lane, Josiah Thompson, Robert Groden, Jim Marrs and Gaeton Fonzi. Jack Duffy is a trial lawyer from Ft. Worth, Texas. He specializes in personal injury and criminal defense law. He was born in Bertram, Texas and grew up in Ft. Worth. He graduated from Paschal High School in Ft. Worth, Texas, and Texas Tech University with a BA in Political Science. It was at Texas Tech that Jack met Vincent Bugliosi. Mr. Bugliosi was giving a speech on the Charles Manson trial. Mr. Bugliosi influenced Mr. Duffy to become a lawyer. Mr. Duffy went on to graduate from Baylor University with a MBA and then graduated from South Texas College of Law with a JD. "The Man From 2063" is his first book. Jack Duffy, JFK Assassination Expert to discuss.....•Conspiracy Theories behind the murder of President John F. Kennedy•Medical evidence in the JFK assassination•Eyewitness testimony in the JFK murder•Photographic evidence in the JFK murder•Deaths of key witnesses in the JFK murder•The time travel aspect of Jack's new book•His new book and its premise, "The Single Bullet Theory"Jack Duffy Credentials•40 years of research on the JFK murder.•Jack has interviewed many key witnesses and doctors who treated JFK.•Mr. Duffy has one of the largest private book collections on the assassination. Please SUBSCRIBE!!!! If you like this show you can find more just like it in The Opperman Report Members Section: http://www.oppermanreport.com/members/ Please support our SPONORS:Pacific West Bamboohttp://www.pacificwestbamboo.com/New World Mexican Womenhttp://handcrafted-ethnic-jewelry.com/new-world-mexican-women/Straw Man!http://www.strawmanmusic.com/Opperman Investigations Inchttp://www.emailrevealer.com/ You can have your business or web site promoted for as little at $25 per week. Or if you enjoyed our show and would like to support our efforts please make a PayPal donation OppermanReport@Gmail.comThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/1198501/advertisement

Game Changers 2014 Predictions Part 3

Play Episode Listen Later Jan 22, 2014 59:57

Looking for a crystal ball to help you predict what 2014 may bring for your business, your industry, your marketplace? We've got the next best thing – dozens of expert insights into the technologies, strategies, and trends that can help you grow and compete better this year and beyond. These thought leaders will appear on SAP Game-Changers Radio 2014 Predictions – Part 3 LIVE: Todd Wilms, SAP; Michael Denis, Flatirons Solutions; Neal Schact, CommuniTech; Nicolette Van Exel, SAP; Kathy-Ann Hutson, IBM; Padman Ramankutty, Intrigo; Steve Hilton, MachNation; Bill Newman, Newport Consulting; China Gorman, Great Place to Work; Steve Player, Beyond Budgeting Round Table; Jorge Garcia, TEC; Dennis Goodhart, IP Network Consulting; Marcus Baur, Sailing Team Germany; Eric Siegel, Predictive Analytics World; Tim Minahan, SAP. To hear the first two parts of our 2014 Predictions special, visist: http://bit.ly/Predictions2014A and http://bit.ly/Predictions2014B. Wishing you a positively game-changing New Year!

new year business technology work predictions ibm game changers wishing sap great places tec voiceamerica jorge garcia steve hilton internet talk radio communitech eric siegel 2014 predictions intrigo bill newman bonnie graham predictive analytics world sap game-changers radio china gorman beyond budgeting round table

Game Changers 2014 Predictions Part 3

Play Episode Listen Later Jan 22, 2014 59:57

Looking for a crystal ball to help you predict what 2014 may bring for your business, your industry, your marketplace? We've got the next best thing – dozens of expert insights into the technologies, strategies, and trends that can help you grow and compete better this year and beyond. These thought leaders will appear on SAP Game-Changers Radio 2014 Predictions – Part 3 LIVE: Todd Wilms, SAP; Michael Denis, Flatirons Solutions; Neal Schact, CommuniTech; Nicolette Van Exel, SAP; Kathy-Ann Hutson, IBM; Padman Ramankutty, Intrigo; Steve Hilton, MachNation; Bill Newman, Newport Consulting; China Gorman, Great Place to Work; Steve Player, Beyond Budgeting Round Table; Jorge Garcia, TEC; Dennis Goodhart, IP Network Consulting; Marcus Baur, Sailing Team Germany; Eric Siegel, Predictive Analytics World; Tim Minahan, SAP. To hear the first two parts of our 2014 Predictions special, visist: http://bit.ly/Predictions2014A and http://bit.ly/Predictions2014B. Wishing you a positively game-changing New Year!

new year business technology work predictions ibm game changers wishing sap great places tec voiceamerica jorge garcia steve hilton internet talk radio communitech eric siegel 2014 predictions intrigo bill newman bonnie graham predictive analytics world sap game-changers radio china gorman beyond budgeting round table

SAPGameChangersRadio from SAPPHIRE Orlando: Bill Newman